var title_f4_37_4688="Model of inspiration";
var content_f4_37_4688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Model of inspiration with respect to the volume/time cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a patient breathing 20 breaths per minute with an I:E ratio of 1:2 and assuming no dwell time between breaths, the last 150 mL of inspired gas which fills the dead space requires about one-half the inspiratory time while the first part of the breath, representing about 0.5 seconds in this schematic, is the actual gas that reaches the alveoli and participates in gas exchange. Note that the very first gas in the airways is air that was exhaled from the alveoli. It is oxygen poor and CO",
"    <sub>",
"     2",
"    </sub>",
"    rich.",
"    <div class=\"footnotes\">",
"     V",
"     <sub>",
"      D",
"     </sub>",
"     : dead space; V",
"     <sub>",
"      A",
"     </sub>",
"     : volume of air that reaches the alveoli and participates in gas exchange; I:E: inspiratory:expiratory ratio.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tiep BL. Continuous flow oxygen therapy and basis for improving the efficiency of oxygen delivery. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Futura Publishing, Mt Kisco, New York, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4688=[""].join("\n");
var outline_f4_37_4688=null;
var title_f4_37_4689="Flock workers lung CT - Nodular consolidation";
var content_f4_37_4689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flock worker's lung CT - Nodular consolidation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 301px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Nodular consolidation around the bronchovascular bundle.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Kern, MD and Robert Crausman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4689=[""].join("\n");
var outline_f4_37_4689=null;
var title_f4_37_4690="Diffuse panbronchiolitis CT";
var content_f4_37_4690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse panbronchiolitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High resolution CT scan in a patient with diffuse panbronchiolitis shows diffuse centrilobular nodular opacities. Some of these opacities are connected to branching structures (tree in bud appearance).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4690=[""].join("\n");
var outline_f4_37_4690=null;
var title_f4_37_4691="Hyaluronidase: Patient drug information";
var content_f4_37_4691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hyaluronidase: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=see_link\">",
"     see \"Hyaluronidase: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/51/23349?source=see_link\">",
"     see \"Hyaluronidase: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amphadase&trade;;",
"     </li>",
"     <li>",
"      Hylenex;",
"     </li>",
"     <li>",
"      Vitrase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13927496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691376",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help other drugs get into the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702246",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hyaluronidase or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11538 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4691=[""].join("\n");
var outline_f4_37_4691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13927496\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012131\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012130\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012135\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012136\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012138\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012133\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012140\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/33/42512?source=related_link\">",
"      Hyaluronidase: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/51/23349?source=related_link\">",
"      Hyaluronidase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_37_4692="Height velocity in boys";
var content_f4_37_4692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Height velocity in American boys",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 700px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Height velocity by age for American boys. Red line: 50th centile for boys maturing 2 SD earlier than the mean; Green line: 50th centile for boys maturing 2 SD later than the mean. Other lines show the 3rd (purple) through 97th (blue) centiles for boys maturing at an average time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tanner JM, Davies S. Clinical longitudinal standards for height and height velocity for North American children. J Pediatr 1985; 107:317. Copyright &copy; 1985 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4692=[""].join("\n");
var outline_f4_37_4692=null;
var title_f4_37_4693="Large CMN";
var content_f4_37_4693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50057&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant congenital melanocytic nevus in a bathing trunk distribution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypertrichosis and multiple satellite congenital nevi are evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Yale Dermatology Residents' Slide Collection.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4693=[""].join("\n");
var outline_f4_37_4693=null;
var title_f4_37_4694="Anterior retraction thyroid";
var content_f4_37_4694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50925&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Anterior retraction thyroid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 448px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anterior/medial retraction of thyroid, showing recurrent laryngeal nerve and parathyroid gland anatomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Clark O. Fine needle aspiration biopsy of the thyroid: Thyroid lobectomy and subtotal and total thyroidectomy. In: Mastery of Surgery, Fischer JE, Bland KI, Callery MP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4694=[""].join("\n");
var outline_f4_37_4694=null;
var title_f4_37_4695="Muscle disease in HIV-infected patients";
var content_f4_37_4695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Muscle disease in HIV-infected patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4695/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4695/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4695/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4695/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/37/4695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 13, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe wasting from repeated infections, malignancy, malabsorption, and nutritional deficiency often account for weakness and disability in patients with the acquired immunodeficiency syndrome (AIDS). Such wasting leads to loss of lean body and muscle mass and may contribute to weakness. The management of AIDS-associated wasting is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=see_link\">",
"     \"Management of tissue wasting in patients with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weakness may also be due to central and peripheral nervous system involvement from infections or immunologically mediated neuropathies in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the possibility of skeletal muscle disease should not be overlooked since several specific skeletal muscle disorders causing weakness have been identified in HIV-infected patients (",
"    <a class=\"graphic graphic_table graphicRef66644 \" href=\"UTD.htm?29/39/30331\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV myopathy",
"     </li>",
"     <li>",
"      Nucleoside reverse transcriptase inhibitor (NRTI) myopathy",
"     </li>",
"     <li>",
"      Muscle infections",
"     </li>",
"     <li>",
"      Other muscle disorders such as rhabdomyolysis, non-Hodgkin lymphoma, myasthenia gravis, nemaline (rod) myopathy and inclusion body myositis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The various forms of muscle disease in patients infected with HIV will be reviewed here. The arthritis associated with HIV infection is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=see_link\">",
"     \"Specific viruses that cause arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HIV MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A myopathy resembling idiopathic polymyositis (PM) can occur in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a review of almost 5000 HIV-infected patients, myopathy was present in 0.2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/4\">",
"     4",
"    </a>",
"    ]. Affected patients present with myalgias, muscle tenderness, and symmetric proximal muscle weakness with a predilection for the lower extremities. Myopathy may be the presenting manifestation of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/5\">",
"     5",
"    </a>",
"    ], or may occur in the setting of already established AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/6\">",
"     6",
"    </a>",
"    ]. The development of myopathy does",
"    <strong>",
"     not",
"    </strong>",
"    correlate with the degree of immunosuppression or the level of CD4+ T cells in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of HIV myositis has not been established. It is possible that muscle damage is caused by direct invasion of muscle cells by HIV itself, a cell-mediated immunologic mechanism, or some combination of both. The direct invasion theory is supported by studies of simian AIDS; infected monkeys develop a myopathy in which the putative retrovirus has been isolated from muscle tissue and shown to be capable of infecting normal muscle in tissue culture [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, attempts to identify HIV antigens in human muscle cells by electron microscopy or immunocytochemical techniques have been unsuccessful. Antigen has been demonstrated in T cells infiltrating the muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/7\">",
"     7",
"    </a>",
"    ], and HIV DNA has been demonstrated in muscle tissue after amplification by polymerase chain reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inability to identify HIV directly in muscle tissue could be due to sampling variability. Alternatively, HIV invasion of muscle may be transient but able to induce an antigenic change in muscle tissue that subsequently triggers an immunologically-mediated inflammatory infiltrate and myositis. It has been suggested that the cases of rhabdomyolysis reported in early HIV infection or with HIV seroconversion (see below) are evidence of direct viral invasion and damage to muscle early in the course of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MHC class I antigens are expressed on both infiltrating CD8+ T cells and muscle cells in patients with HIV myopathy. In addition, activated T cells release cytokines that stimulate the expression of class I antigens on muscle cells that are then recognized by cytotoxic CD8+ T cells. These changes also occur in idiopathic PM, suggesting that, in both diseases, a T-cell mediated MHC restricted cytotoxic immune process is responsible (at least in part) for the myopathic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical challenge in making the diagnosis of HIV myopathy may involve distinguishing between this disorder and NRTI myopathy (see below). Successful distinction often requires a trial of stopping NRTIs and monitoring the response. Muscle enzymes are typically increased up to 10-fold in patients with both disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=see_link\">",
"     \"Muscle enzymes in the evaluation of neuromuscular diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electromyography and muscle biopsy may assist in making the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electromyography in patients with HIV myopathy shows myopathic changes with increased insertional activity, fibrillations, and polyphasic potentials characteristic of membrane irritability and indistinguishable from idiopathic PM.",
"     </li>",
"     <li>",
"      Histologic changes on muscle biopsy include an endomysial mononuclear cell infiltrate with lesser accumulation of inflammatory cells around vessels or in the interfascicular space (",
"      <a class=\"graphic graphic_picture graphicRef69212 \" href=\"UTD.htm?0/43/696\">",
"       picture 1",
"      </a>",
"      ). The cellular infiltrate is predominantly CD8+ T lymphocytes and macrophages.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV myopathy appears to have a better prognosis than idiopathic PM with some patients improving spontaneously. Asymptomatic patients may require no treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    High-dose steroids, as used in idiopathic PM, have been shown to be effective in HIV myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/3,5,6\">",
"     3,5,6",
"    </a>",
"    ]. Corticosteroid therapy is initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in a dose of 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Normalization of muscle enzymes and improvement in strength in responders usually occur within one to two months of corticosteroid therapy. Treatment of steroid non-responders is uncertain. Three patients with suboptimal response to corticosteroids in one report did not respond to IVIG although they did have a subsequent spontaneous improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/4\">",
"     4",
"    </a>",
"    ]. Immunosuppressive agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , which are employed in this setting in idiopathic PM, must be used very carefully in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once the full response has occurred,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is tapered gradually, while the patient's muscle strength and plasma enzymes are monitored for signs of relapse. There is no standard tapering schedule, but one reasonable approach is to decrease by 5",
"    <span class=\"nowrap\">",
"     mg/week",
"    </span>",
"    down to 20",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    then by 2.5 mg every two weeks down to 10",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and then by one",
"    <span class=\"nowrap\">",
"     mg/month",
"    </span>",
"    until steroids are discontinued. Alternate day steroids (50 to 60 mg every other day) can be used from the outset in mild cases, or after the disease is well controlled in more severe cases.",
"   </p>",
"   <p>",
"    The patient should be carefully monitored during the tapering period, watching for signs of recurrent weakness and for signs of corticosteroid toxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .) Alternative diagnoses and steroid myopathy should be considered in patients who fail to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (eg, do not achieve normalizations of muscle enzymes and the return of muscle strength). The latter diagnosis is suggested by weakness in the setting of normal muscle enzymes. An empiric trial of lowering the prednisone dose and observing the muscle strength response is an effective and practical approach to this dilemma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NRTI MYOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Originally described with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (ZDV), HIV nucleoside reverse transcriptase inhibitors (NRTIs) are associated with a myopathy that clinically resembles idiopathic PM and HIV myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Affected patients present with myalgias, muscle tenderness, proximal muscle weakness, and often prominent muscle atrophy. NRTI myopathy was more common in the past when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    , in particular, was used at higher doses than are currently administered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/13,15\">",
"     13,15",
"    </a>",
"    ]. Other NRTIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , appear to be weaker inhibitors of mitochondrial function than zidovudine and have not been associated with myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis should be suspected in patients who develop characteristic clinical features in the setting of months of NRTI therapy. CK levels are elevated usually up to 10-fold normal, overlapping with HIV myopathy. EMG may demonstrate mild myopathic changes or is normal.",
"   </p>",
"   <p>",
"    In contrast to patients with HIV myopathy, light microscopy of the affected muscle in patients with ZDV myopathy generally shows no inflammatory infiltrate or a very mild endomysial collection of T lymphocytes, scattered muscle fiber necrosis, and variable muscle fiber atrophy. Most investigators have found evidence of a mitochondrial myopathy, which may result from NRTI-induced inhibition of mitochondrial DNA synthesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If NRTI myopathy is suspected clinically or evidence of a mitochondrial myopathy is found on muscle biopsy, the response to discontinuing the drug should be determined. Muscle enzymes and strength generally return to normal one to two months after the drug is discontinued in patients with ZDV myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/13\">",
"     13",
"    </a>",
"    ]. If there is partial or no response to discontinuing the drug, it is likely that HIV myopathy is present.",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs may help to relieve myalgias pending the response to cessation of the NRTI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/13\">",
"     13",
"    </a>",
"    ]. There is in vitro evidence that administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     carnitine",
"    </a>",
"    may both prevent the development of ZDV myopathy, and prevent progression with continued ZDV administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The clinical efficacy of this approach remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MUSCLE INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pyomyositis due to pyogenic bacteria has been reported in patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/19\">",
"     19",
"    </a>",
"    ]. While these infections may sometimes cause diagnostic confusion with HIV or NRTI myopathies, skeletal muscle involvement is usually more focal with infections, and localized muscle tenderness and swelling are more prominent findings than true muscle weakness. Staphylococcus aureus is the most common cause of pyomyositis, and the diagnosis is generally established by CT scan, ultrasound, or MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"     \"Pyomyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Toxoplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle infection with toxoplasmosis may present more similarly to HIV and NRTI myopathies than to other muscle infections (",
"    <a class=\"graphic graphic_table graphicRef66644 \" href=\"UTD.htm?29/39/30331\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/20\">",
"     20",
"    </a>",
"    ]. Diffuse muscle wasting, weakness, and tenderness commonly occur, often in association with central nervous system toxoplasmosis. Muscle enzymes are usually elevated.",
"   </p>",
"   <p>",
"    Muscle biopsy shows necrosis and a variable degree of inflammation, usually with more neutrophils present than in idiopathic PM or HIV myopathy. The presence of intracellular cysts containing T. gondii organisms establishes the diagnosis. Toxoplasma serology may be positive.",
"   </p>",
"   <p>",
"    Since toxoplasmosis infection of muscle responds to appropriate antibiotic therapy, it is important to consider this diagnosis in HIV-infected patients presenting with myopathy. Such patients typically have disseminated toxoplasmosis and may have involvement of the central nervous system. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/51/23350?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    is the regimen of choice for treatment of extrapulmonary toxoplasmosis. A 200 mg loading dose of pyrimethamine is given initially and is followed by 50 to 75",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    while sulfadiazine is given at 4 to 6",
"    <span class=\"nowrap\">",
"     grams/day.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     Leucovorin",
"    </a>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally) is usually given to reduce the hematologic toxicity of these drugs.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    (at a dose of 600 mg every six hours) can be used in combination with pyrimethamine in patients with sulfa intolerance. Side effects of these drugs are common (",
"    <a class=\"graphic graphic_table graphicRef75331 \" href=\"UTD.htm?18/38/19051\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     OTHER MUSCLE DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other muscle disorders may be seen in association with HIV infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is a syndrome of extensive muscle necrosis associated with myoglobinuria and acute renal failure. It has numerous causes in the non-HIV-infected patient including trauma and crush injuries, seizures, alcohol or cocaine abuse, viral myositis, drug-induced myositis, pyomyositis, inherited metabolic myopathies, and electrolyte abnormalities (such as hypokalemia and hypophosphatemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"     \"Drug-induced myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhabdomyolysis may be seen in HIV infected patients in a variety of circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]. A review of 20 reported cases found that rhabdomyolysis occurred at all stages of HIV infection, and could be classified into three groups with roughly equal frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-associated rhabdomyolysis, including rhabdomyolysis associated with primary HIV infection, recurrent rhabdomyolysis, and isolated rhabdomyolysis",
"     </li>",
"     <li>",
"      Drug-induced rhabdomyolysis due to drug interactions between certain statins and HIV protease inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"       \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rhabdomyolysis at the end stage of AIDS, including opportunistic infections of muscle and rhabdomyolysis without a definite cause",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, seizures and electrolyte disturbances may precipitate rhabdomyolysis at any stage of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-Hodgkin lymphoma may present as a localized, painful muscle mass. This needs to be distinguished from other causes of localized limb swelling including pyomyositis, deep venous thrombosis, and Kaposi's sarcoma originating in skeletal muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/28\">",
"     28",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) may help to distinguish infectious causes of localized muscle swelling from neoplasms; the finding of a hyperintense ring around the mass on T1-weighted images favors pyomyositis, while prominent involvement of subcutaneous tissue favors lymphoma or Kaposi's sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myasthenia gravis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myasthenia gravis has been reported in a few patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/30\">",
"     30",
"    </a>",
"    ]. It is unclear whether this was a coincidence or an immunologically-mediated manifestation of HIV infection. Affected patients responded to anticholinesterase therapy, In most cases, the myasthenia was transient and improved in parallel with progressive immunodeficiency and declining CD4+ cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nemaline (rod) myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nemaline (rod) myopathy is a rare disorder in adults without HIV infection, and there have been case reports in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/6,31,32\">",
"     6,31,32",
"    </a>",
"    ]. These patients present with a slowly progressive proximal myopathy, mildly elevated serum CK concentrations, and a characteristic muscle biopsy showing abundant nemaline bodies or rod structures in atrophic fibers on electron microscopy. Inflammatory changes are either not present or are very mild. In some reported cases, there has been a response to corticosteroids in doses similar to those used for HIV myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/6,32\">",
"     6,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a congenital form of nemaline myopathy, which is usually inherited as an autosomal recessive trait. The nemaline bodies are composed of proteins derived from the thin filament and Z disc. The primary defect in this disorder appears to be a mutation in the nebulin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/33\">",
"     33",
"    </a>",
"    ]. The nebulin protein is found in the thin filaments of skeletal muscle.",
"   </p>",
"   <p>",
"    An autosomal dominant form has also been described in which the defect is in the alpha-tropomyosin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/34\">",
"     34",
"    </a>",
"    ]. The myopathy in this setting is associated with reduced calcium-induced sensitivity to contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inclusion body myositis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of cases of inclusion body myositis (IBM) have been reported in patients with HIV and with other retroviral infections including HTLV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4695/abstract/36\">",
"     36",
"    </a>",
"    ]. The clinical presentation and muscle histopathology are identical to sporadic IBM. Clinical symptoms include insidious onset of proximal muscle weakness followed by distal extremity weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=see_link\">",
"     \"Clinical manifestations and diagnosis of inclusion body myositis\"",
"    </a>",
"    .) Muscle biopsy demonstrates viral-specific CD8+ T cell clones invading muscle fibers, supporting the hypothesis that IBM is mediated by viral infection in genetically susceptible individuals.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/1\">",
"      Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988; 23 Suppl:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/2\">",
"      Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve 2005; 32:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/3\">",
"      Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis associated with AIDS retrovirus. JAMA 1986; 256:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/4\">",
"      Johnson RW, Williams FM, Kazi S, et al. Human immunodeficiency virus-associated polymyositis: a longitudinal study of outcome. Arthritis Rheum 2003; 49:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/5\">",
"      Glickstein SL, Strickland SR, Rusin LH. Acute myositis in a patient with the acquired immunodeficiency syndrome. Arthritis Rheum 1990; 33:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/6\">",
"      Simpson DM, Bender AN. Human immunodeficiency virus-associated myopathy: analysis of 11 patients. Ann Neurol 1988; 24:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/7\">",
"      Illa I, Nath A, Dalakas M. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 1991; 29:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/8\">",
"      Dalakas MC, London WT, Gravell M, Sever JL. Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus. Neurology 1986; 36:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/9\">",
"      Dalakas MC, Gravell M, London WT, et al. Morphological changes of an inflammatory myopathy in rhesus monkeys with simian acquired immunodeficiency syndrome. Proc Soc Exp Biol Med 1987; 185:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/10\">",
"      Seidman R, Peress NS, Nuovo GJ. In situ detection of polymerase chain reaction-amplified HIV-1 nucleic acids in skeletal muscle in patients with myopathy. Mod Pathol 1994; 7:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/11\">",
"      Reveille JD. The changing spectrum of rheumatic disease in human immunodeficiency virus infection. Semin Arthritis Rheum 2000; 30:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/12\">",
"      Dalakas MC, Illa I, Pezeshkpour GH, et al. Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/13\">",
"      Peters BS, Winer J, Landon DN, et al. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS. Q J Med 1993; 86:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/14\">",
"      Chariot P, Gherardi R. Myopathy and HIV infection. Curr Opin Rheumatol 1995; 7:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/15\">",
"      HIV Neuromuscular Syndrome Study Group. HIV-associated neuromuscular weakness syndrome. AIDS 2004; 18:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/16\">",
"      Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005; 10 Suppl 2:M47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/17\">",
"      Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest 1994; 71:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/18\">",
"      Semino-Mora MC, Leon-Monzon ME, Dalakas MC. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest 1994; 71:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/19\">",
"      Widrow CA, Kellie SM, Saltzman BR, Mathur-Wagh U. Pyomyositis in patients with the human immunodeficiency virus: an unusual form of disseminated bacterial infection. Am J Med 1991; 91:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/20\">",
"      Gherardi R, Baudrimont M, Lionnet F, et al. Skeletal muscle toxoplasmosis in patients with acquired immunodeficiency syndrome: a clinical and pathological study. Ann Neurol 1992; 32:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/21\">",
"      Mah&eacute; A, Bruet A, Chabin E, Fendler JP. Acute rhabdomyolysis coincident with primary HIV-1 infection. Lancet 1989; 2:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/22\">",
"      Curtis M, Gill MJ, Brownell AK. Polymyositislike syndromes in acquired immunodeficiency syndrome. Arch Neurol 1989; 46:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/23\">",
"      Chariot P, Ruet E, Authier FJ, et al. Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology 1994; 44:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/24\">",
"      Wu AW, Benirschke K, McCutchan JA. Rhabdomyolysis and Staphylococcus aureus septicemia in a man with the acquired immunodeficiency syndrome. West J Med 1990; 152:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/25\">",
"      Sesma P, Martinez G, Verdejo C, Fernandez-Guerrero ML. Rhabdomyolysis, infection due to the human immunodeficiency virus, and staphylococcal bacteremia. Clin Infect Dis 1992; 15:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/26\">",
"      Delo D, Brett AS, Postic B. Primary HIV infection presenting with acute rhabdomyolysis. Am J Med Sci 2006; 332:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/27\">",
"      Mikhail N, Iskander E, Cope D. Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf 2009; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/28\">",
"      Chevalier X, Amoura Z, Viard JP, et al. Skeletal muscle lymphoma in patients with the acquired immunodeficiency syndrome: a diagnostic challenge. Arthritis Rheum 1993; 36:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/29\">",
"      Fleckenstein JL, Burns DK, Murphy FK, et al. Differential diagnosis of bacterial myositis in AIDS: evaluation with MR imaging. Radiology 1991; 179:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/30\">",
"      Authier FJ, De Grissac N, Degos JD, Gherardi RK. Transient myasthenia gravis during HIV infection. Muscle Nerve 1995; 18:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/31\">",
"      Dalakas MC, Pezeshkpour GH, Flaherty M. Progressive nemaline (rod) myopathy associated with HIV infection. N Engl J Med 1987; 317:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/32\">",
"      Dwyer BA, Mayer RF, Lee SC. Progressive nemaline (rod) myopathy as a presentation of human immunodeficiency virus infection. Arch Neurol 1992; 49:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/33\">",
"      Pelin K, Hilpel&auml; P, Donner K, et al. Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci U S A 1999; 96:2305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/34\">",
"      Laing NG, Wilton SD, Akkari PA, et al. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy. Nat Genet 1995; 9:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/35\">",
"      Michele DE, Albayya FP, Metzger JM. A nemaline myopathy mutation in alpha-tropomyosin causes defective regulation of striated muscle force production. J Clin Invest 1999; 104:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4695/abstract/36\">",
"      Dalakas MC, Rakocevic G, Shatunov A, et al. Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells. Ann Neurol 2007; 61:466.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3719 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4695=[""].join("\n");
var outline_f4_37_4695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HIV MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NRTI MYOPATHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MUSCLE INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Toxoplasmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      OTHER MUSCLE DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nemaline (rod) myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3719\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3719|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/43/696\" title=\"picture 1\">",
"      Muscle biopsy polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3719|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/39/30331\" title=\"table 1\">",
"      HIV associated myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/38/19051\" title=\"table 2\">",
"      Regimens for toxoplasmosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/23/15735?source=related_link\">",
"      Clinical manifestations and diagnosis of inclusion body myositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/37/42584?source=related_link\">",
"      Management of tissue wasting in patients with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36745?source=related_link\">",
"      Muscle enzymes in the evaluation of neuromuscular diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23354?source=related_link\">",
"      Specific viruses that cause arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_37_4696="Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane";
var content_f4_37_4696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Recovery of renal function and effect of hemodialysis membrane",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Paul M Palevsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4696/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/37/4696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis may be required in patients with severe acute renal failure. Mortality in such patients is often associated with infection or bleeding. Since these problems can be exacerbated by uremia, it has been suggested that dialysis begun before evidence of overt uremia may lead to improved survival. This issue is complicated by evidence that dialysis may delay the recovery of renal function.",
"   </p>",
"   <p>",
"    This topic will review concerns related to whether dialysis delays the recovery of renal function as well as the effects of different hemodialysis membranes. An overview of supportive management in acute kidney injury is also presented.",
"   </p>",
"   <p>",
"    The indications for and optimal timing and dose of dialysis in acute renal failure as well as the metabolic and hemodynamic changes associated with dialysis in acute renal failure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing dialysis in acute renal failure, an overview of general issues in non-dialytic management of patients with established acute renal failure is indicated. The basic goals for the management of established acute renal failure are the maintenance of fluid and electrolyte balance, avoidance of nephrotoxic medications, adequate nutrition, treatment of infections, correction of reversible prerenal (eg, hypovolemia) and postrenal factors, close monitoring, and proper dosing of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperkalemia and fluid overload are more likely to occur in oliguric patients. Problems with hyperkalemia can be minimized by restriction of potassium intake, avoidance of potassium containing and sparing drugs, and appropriate treatment of hyperkalemia. Although hyperkalemia and metabolic acidosis can initially be treated medically, dialysis is usually required to adequately manage these abnormalities in patients with acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=see_link\">",
"     \"Clinical manifestations of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=see_link\">",
"     \"Treatment and prevention of hyperkalemia in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Indications for dialysis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Sodium and water intake should be matched to urinary and insensible losses. When estimating insensible losses, it is important to take into account endogenous water formation due to the metabolism of proteins, carbohydrates, and fats (to carbon dioxide and water) and to intracellular water released from cell catabolism. Although insensible losses may be 1000",
"    <span class=\"nowrap\">",
"     mL/day,",
"    </span>",
"    endogenous water formation averages 450",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"    As a result, only approximately 400 to 500 mL of water has to be replaced in the absence of fever or hyperventilation. The role of diuretics in volume control is discussed separately, but caution should be exercised in using diuretics to achieve these goals [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=see_link\">",
"     \"Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=see_link\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although erythropoietic stimulating agents (ESAs) are commonly used for the treatment of anemia in patients with chronic kidney disease, it is unclear if this agent provides benefits in those with acute renal failure. A retrospective cohort study reported the outcomes of 187 patients with acute renal failure of whom 71 were administered erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/3\">",
"     3",
"    </a>",
"    ]. Recovery of renal function and transfusion requirements were similar in both groups. Study limitations included retrospective design and inadequate dosing and treatment duration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/4\">",
"     4",
"    </a>",
"    ]. Further study is required to better understand the role of ESAs in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Providing adequate nutrition to patients with acute renal failure who require renal replacement therapy may necessitate parenteral or enteral nutrition. Among critically ill patients without acute renal failure, most clinicians feel that enteral nutrition should be employed in preference to parenteral nutrition whenever possible because of its lower cost, less frequent and severe complications, less mucosal permeability, greater wound healing, and lower rates of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with acute renal failure, there are limited data concerning the efficacy and safety of enteral nutrition. In one study, enteral nutrition-related outcomes were compared among 247 consecutive patients fed enterally: 114 required renal replacement therapy (RRT); 68 had acute renal failure but did not require RRT; and 65 had normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/5\">",
"     5",
"    </a>",
"    ]. Other than an increased incidence of nasogastric tube obstruction and high gastric residual volumes among patients requiring RRT, there was no difference in gastrointestinal and mechanical complications in the three groups. The mean amount of nonprotein and protein calories for RRT patients were 23.4",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    and 0.92",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    respectively, with the amount of delivered protein calories being slightly less than currently recommended. This can be overcome by administering parenteral amino acids during daily RRT.",
"   </p>",
"   <p>",
"    Adequate nutrition is a significant part of the therapy of patients with acute renal failure, with poor nutrition contributing to increased mortality. Although requirements vary based upon the underlying catabolic state, some investigators feel that patients need approximately 25 to 35",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day. Others, however, feel that permissive underfeeding may actually be a preferred approach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/6\">",
"     6",
"    </a>",
"    ], despite the lack of specific data on underfeeding in acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/7\">",
"     7",
"    </a>",
"    ]. With this approach, the caloric recommendations are lower, such as 15 to 20",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day for the first three to five days, which is then advanced to 20 to 25",
"    <span class=\"nowrap\">",
"     kcal/kg",
"    </span>",
"    per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CAN DIALYSIS DELAY RECOVERY OF RENAL FUNCTION?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is at least theoretical concern that dialysis might have",
"    <strong>",
"     detrimental effects",
"    </strong>",
"    on renal function. Three factors may be important in this regard: a reduction in urine output; induction of hypotension; and complement activation resulting from a blood-dialysis membrane interaction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fall in urine output",
"    </span>",
"    &nbsp;&mdash;&nbsp;The institution of dialysis in acute renal failure frequently leads to a reduction in or even cessation of the urine output. Both removal of excess volume and of urea contribute to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/10\">",
"     10",
"    </a>",
"    ]. Urea may be a surrogate marker of other substances that are removed by dialysis which stimulate urine output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=see_link\">",
"     \"Urine output and residual renal function in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of induction of oliguria on renal function in this setting is uncertain. Although there is no definitive answer to this question, it seems unlikely that lowering the urine output will impair the recovery of overall renal function. A patient with acute renal failure who requires dialysis has less than 5 percent of his or her nephrons functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/11\">",
"     11",
"    </a>",
"    ]. The decline in urine output following dialysis reflects an increase in tubular reabsorption in these few nephrons. Even if the function of these nephrons became impaired (perhaps because slow flow may promote obstruction by tubular debris), the fall in urine output should not delay the regeneration of tubules and the restoration of function in the 95 percent of nephrons that are currently nonfunctioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Repeated episodes of hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is a common complication of hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .) This may be a particular problem in the kidney with ATN, which appears to be particularly sensitive to diminished perfusion. Normal kidneys vasodilate in the presence of ischemia as part of the autoregulatory response to maintain renal blood flow and glomerular filtration rate near the baseline level. Autoregulation is impaired in ATN, perhaps because vascular endothelial injury reduces the release of vasodilating substances such as prostacyclin and nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. As a result, recurrent ischemic tubular injury is more likely to occur, thereby delaying the restoration of function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/8,14,15\">",
"     8,14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fluid removal is slower and hypotension is uncommon with peritoneal dialysis and other continuous renal replacement therapies. It has been suggested that the latter modalities may be associated with an improved outcome, due perhaps to more stable hemodynamics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; however, this has not been rigorously demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complement activation, membrane biocompatibility, renal recovery, and survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;A third possible mechanism of dialysis-induced renal injury has been suggested from animal models. Complement activation during the blood-dialyzer interaction with cuprophane membranes (but not more compatible membranes) can lead to neutrophilic infiltration into the kidney (and other tissues) and prolonged acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/19\">",
"     19",
"    </a>",
"    ]. This effect may be mediated in part by upregulation of adhesion molecules on granulocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/20\">",
"     20",
"    </a>",
"    ]. The importance of this response is suggested by experimental studies demonstrating the ability of antibodies to intercellular adhesion molecule-1 (ICAM-1) to protect against ischemic renal injury; a similar degree of protection is seen in mutant mice that are deficient in ICAM-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=see_link\">",
"     \"Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These membrane reactions appear to be important in humans with ATN [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. In one multicenter prospective study, 153 patients with acute kidney injury who required dialysis were randomized to therapy with a biocompatible or bioincompatible hemodialysis membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/24\">",
"     24",
"    </a>",
"    ]. At equivalent disease severity, the following benefits were noted in patients treated with biocompatible membranes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A higher rate of recovery of renal function (64 versus 43 percent)",
"     </li>",
"     <li>",
"      An improvement in patient survival (57 versus 46 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits were limited to patients who were nonoliguric prior to the onset of hemodialysis. In addition, among nonoliguric patients, a more rapid recovery was observed for those dialyzed with biocompatible membranes as evidenced by fewer mean dialysis treatments before recovery (4 versus 15). Furthermore, in nonoliguric patients, 70 percent became oliguric on bioincompatible membranes, while only 44 percent did so on biocompatible membranes.",
"   </p>",
"   <p>",
"    Nonoliguric ATN is known to be a less severe disease in which there are more functioning nephrons than in oliguric ATN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=see_link\">",
"     \"Nonoliguric versus oliguric acute tubular necrosis\"",
"    </a>",
"    .) It is possible that better preserved kidneys with a higher rate of renal perfusion are more susceptible to injury-induced by activated complement and neutrophils.",
"   </p>",
"   <p>",
"    A similar reduction in mortality (35 versus 62 percent) with biocompatible dialysis membranes was demonstrated in a separate prospective trial of critically ill patients with acute renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/23\">",
"     23",
"    </a>",
"    ]. The survival benefit in this setting was primarily due to fewer septic deaths (15 versus 46 percent). How bioincompatible membranes and complement activation might promote infection is not clear. Two possibilities are an impairment in neutrophil function and hypotension which, by reducing intestinal perfusion, might injure the intestinal mucosa and promote bacterial entry into the bloodstream.",
"   </p>",
"   <p>",
"    The more rapid recovery of renal function with biocompatible membranes may be applicable to causes of acute renal failure other than acute tubular necrosis. As examples, many patients with vasculitis and rapidly progressive glomerulonephritis who initially require dialysis recover sufficient function with immunosuppressive therapy for dialysis to be discontinued. In theory, exposure to a bioincompatible membrane and neutrophil activation in these inflammatory conditions might impair the recovery of renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=see_link\">",
"     \"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, not all studies have found that biocompatible membranes lead to better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. As examples,",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter prospective trial, 180 patients with acute renal failure were randomly treated with either bioincompatible cuprophane (90 patients) or biocompatible polymethylmethacrylate (90 patients) membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/27\">",
"       27",
"      </a>",
"      ]. Both groups had similar severity of illness (as determined by APACHE II scores). The principal outcome measure, survival at 14 days, was the same in the two populations.",
"     </li>",
"     <li>",
"      In a second trial, 159 patients with acute renal failure were randomly assigned to dialysis with low-flux polysulfone, high-flux polysulfone, or cellulose diacetate (bioincompatible) membranes [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/28\">",
"       28",
"      </a>",
"      ]. Survival, number of required dialysis sessions, and time to recovery of renal function were similar in the three groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear why there are inconsistent findings concerning the effect of membrane biocompatibility on outcomes among patients with acute renal failure.",
"   </p>",
"   <p>",
"    Several meta-analyses have been performed, with also inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/25,29,30\">",
"     25,29,30",
"    </a>",
"    ]. In a 2005 meta-analysis from the Cochrane database, nine studies with a total of over 1000 patients were reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/29\">",
"     29",
"    </a>",
"    ]. The relative risk for mortality and recovery of renal function was similar with both biocompatible and bioincompatible membranes. These outcomes were also the same with high and low flux membranes.",
"   </p>",
"   <p>",
"    Possible explanations for the discrepant results with the different membranes are that the effect of complement-activating membranes on outcomes is not large",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    requires a long period of follow-up to be detected, or that other prognostic determinants, such as comorbidity or nursing skills, are more significant factors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, given that the effect of biocompatible dialysis membranes (when present) is consistently beneficial and that differences in cost are no longer important, we favor the routine use of biocompatible dialysis membranes in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Membranes can be of low or high flux. High flux membranes contain large pores that allow for enhanced permeability of larger molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this property can enhance removal of putative toxins and improve outcome, it could also allow the back transport (from dialysate to blood) of potentially harmful water-borne molecules. This bidirectional transfer also confounds some of the conclusions reached in multiple studies in the past. Certainly, having the purest dialysate water possible should be a goal when using these more porous membranes to utilize their positive attributes and to minimize their potential risks.",
"   </p>",
"   <p>",
"    Definitive studies of high flux dialysis are available from the chronic hemodialysis population. They suggest that there is no significant difference in outcomes between low and high flux dialysis membranes. Results of the HEMO study can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=see_link\">",
"     \"Dialysis modality and patient outcome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, only preliminary studies concerning low and high flux membranes has been undertaken in patients with acute kidney injury. Available data are insufficient to form clear evidence based recommendations. Small randomized prospective studies have found no difference with low or high flux membranes in terms of survival or recovery of kidney function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, there are theoretical advantages to high flux biocompatible membranes that have not been consistently corroborated by often underpowered or flawed clinical studies. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Complement activation, membrane biocompatibility, renal recovery, and survival'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We therefore suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the water is high quality (ie, with very low levels of bacteria and endotoxin), we suggest that high flux biocompatible dialysis membranes be used in patients with acute kidney injury.",
"     </li>",
"     <li>",
"      If the water is not of high quality, low flux biocompatible dialysis membranes should be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-cutoff-point membranes are being developed that possess greater cytokine removal capacity than standard high flux membranes. One limited study of 10 septic patients and acute kidney injury, for example, found that high-cutoff-point membranes achieved significantly greater decreases in plasma cytokine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4696/abstract/35\">",
"     35",
"    </a>",
"    ]. Further studies with significant clinical outcomes are required to better characterize the role for this membrane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for and optimal timing of dialysis in patients with acute kidney injury are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIALYSIS DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dialysis dose in patients undergoing intermittent hemodialysis or continuous renal replacement therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373486783\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a theoretical concern that dialysis might have detrimental effects on renal function. Three factors that may be important in this regard include a reduction in urine output; induction of hypotension; and complement activation resulting from a blood-dialysis membrane interaction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Can dialysis delay recovery of renal function?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A reduction or cessation of the urine output results in both removal of excess volume and of urea. Urea may be a surrogate marker of other substances that are removed by dialysis which stimulate urine output. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Fall in urine output'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=see_link\">",
"       \"Urine output and residual renal function in renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypotension is a common complication of hemodialysis. This may be a particular problem in recovery of renal function in a patient who has acute tubular necrosis (ATN). Whereas normal kidneys vasodilate in the presence of ischemia as part of the autoregulatory response to maintain renal blood flow and glomerular filtration rate near the baseline level, autoregulation is impaired in ATN, resulting in recurrent ischemic tubular injury, thereby delaying the restoration of function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Repeated episodes of hypotension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement activation during the blood-dialyzer interaction with cuprophane membranes, but not more compatible membranes, can lead to neutrophilic infiltration into the kidney (and other tissues) and prolonged acute kidney injury. We favor the routine use of biocompatible dialysis membranes among patients with acute kidney injury. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Complement activation, membrane biocompatibility, renal recovery, and survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Membranes can be of low or high flux. High flux membranes can enhance removal of putative toxins and improve outcome, but may also allow the back transport (from dialysate to blood) of potentially harmful water-borne molecules. Having the purest dialysate water possible should be a goal when using these more porous membranes to utilize their positive attributes and to minimize their potential risks. If the water used is high quality, we suggest that high flux biocompatible dialysis membranes be used in patients with acute kidney injury. If the water system is not of high quality, low flux biocompatible dialysis membranes should be used. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Membranes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/1\">",
"      Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/2\">",
"      Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288:2547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/3\">",
"      Park J, Gage BF, Vijayan A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis 2005; 46:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/4\">",
"      Kraus E, Rabb H. EPO therapy during acute kidney disease: to use or not to use, that is the question. Am J Kidney Dis 2005; 46:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/5\">",
"      Fiaccadori E, Maggiore U, Giacosa R, et al. Enteral nutrition in patients with acute renal failure. Kidney Int 2004; 65:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/6\">",
"      Krishnan JA, Parce PB, Martinez A, et al. Caloric intake in medical ICU patients: consistency of care with guidelines and relationship to clinical outcomes. Chest 2003; 124:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/7\">",
"      Bellomo R, Seacombe J, Daskalakis M, et al. A prospective comparative study of moderate versus high protein intake for critically ill patients with acute renal failure. Ren Fail 1997; 19:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/8\">",
"      Conger JD. Interventions in clinical acute renal failure: what are the data? Am J Kidney Dis 1995; 26:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/9\">",
"      Star RA. Treatment of acute renal failure. Kidney Int 1998; 54:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/10\">",
"      Yeh BP, Tomko DJ, Stacy WK, et al. Factors influencing sodium and water excretion in uremic man. Kidney Int 1975; 7:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/11\">",
"      Finn WF. Nephron heterogeneity in polyuric acute renal failure. J Lab Clin Med 1981; 98:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/12\">",
"      Conger JD, Robinette JB, Schrier RW. Smooth muscle calcium and endothelium-derived relaxing factor in the abnormal vascular responses of acute renal failure. J Clin Invest 1988; 82:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/13\">",
"      Conger JD, Robinette JB, Hammond WS. Differences in vascular reactivity in models of ischemic acute renal failure. Kidney Int 1991; 39:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/14\">",
"      Solez K, Morel-Maroger L, Sraer JD. The morphology of \"acute tubular necrosis\" in man: analysis of 57 renal biopsies and a comparison with the glycerol model. Medicine (Baltimore) 1979; 58:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/15\">",
"      Myers BD, Moran SM. Hemodynamically mediated acute renal failure. N Engl J Med 1986; 314:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/16\">",
"      Barton IK, Hilton PJ, Taub NA, et al. Acute renal failure treated by haemofiltration: factors affecting outcome. Q J Med 1993; 86:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/17\">",
"      Firth JD. Renal replacement therapy on the intensive care unit. Q J Med 1993; 86:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/18\">",
"      Palevsky PM. Dialysis modality and dosing strategy in acute renal failure. Semin Dial 2006; 19:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/19\">",
"      Schulman G, Fogo A, Gung A, et al. Complement activation retards resolution of acute ischemic renal failure in the rat. Kidney Int 1991; 40:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/20\">",
"      Himmelfarb J, Zaoui P, Hakim R. Modulation of granulocyte LAM-1 and MAC-1 during dialysis--a prospective, randomized controlled trial. Kidney Int 1992; 41:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/21\">",
"      Kelly, KJ, Williams, WW Jr, Colvin, RB, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/22\">",
"      Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994; 331:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/23\">",
"      Schiffl H, Lang SM, K&ouml;nig A, et al. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994; 344:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/24\">",
"      Himmelfarb J, Tolkoff Rubin N, Chandran P, et al. A multicenter comparison of dialysis membranes in the treatment of acute renal failure requiring dialysis. J Am Soc Nephrol 1998; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/25\">",
"      Subramanian S, Venkataraman R, Kellum JA. Influence of dialysis membranes on outcomes in acute renal failure: a meta-analysis. Kidney Int 2002; 62:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/26\">",
"      Rom&atilde;o JE Jr, Abensur H, de Castro MC, et al. Effect of dialyser biocompatibility on recovery from acute renal failure after cadaver renal transplantation. Nephrol Dial Transplant 1999; 14:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/27\">",
"      J&ouml;rres A, Gahl GM, Dobis C, et al. Haemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group. Lancet 1999; 354:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/28\">",
"      Gastaldello K, Melot C, Kahn RJ, et al. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure. A prospective randomized study. Nephrol Dial Transplant 2000; 15:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/29\">",
"      Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2005; :CD005283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/30\">",
"      Teehan GS, Liangos O, Lau J, et al. Dialysis membrane and modality in acute renal failure: understanding discordant meta-analyses. Semin Dial 2003; 16:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/31\">",
"      Vanholder R, Lameire N. Does biocompatibility of dialysis membranes affect recovery of renal function and survival? Lancet 1999; 354:1316.",
"     </a>",
"    </li>",
"    <li>",
"     Marshall, MR, Golper, TA. Intermittent Hemodialysis in Intensive Care in Nephrology, Murray, P, Brady, H, Hall, J (Eds), Taylor &amp; Francis, Oxford, UK 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/33\">",
"      Pettil&auml; V, Tiula E. Intermittent hemodiafiltration in acute renal failure in critically ill patients. Clin Nephrol 2001; 56:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/34\">",
"      Ponikvar JB, Rus RR, Kenda RB, et al. Low-flux versus high-flux synthetic dialysis membrane in acute renal failure: prospective randomized study. Artif Organs 2001; 25:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4696/abstract/35\">",
"      Haase M, Bellomo R, Baldwin I, et al. Hemodialysis membrane with a high-molecular-weight cutoff and cytokine levels in sepsis complicated by acute renal failure: a phase 1 randomized trial. Am J Kidney Dis 2007; 50:296.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1938 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-2AD339225F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4696=[""].join("\n");
var outline_f4_37_4696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H373486783\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CAN DIALYSIS DELAY RECOVERY OF RENAL FUNCTION?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fall in urine output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Repeated episodes of hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complement activation, membrane biocompatibility, renal recovery, and survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INDICATIONS FOR DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIALYSIS DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H373486783\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44069?source=related_link\">",
"      Clinical manifestations of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34312?source=related_link\">",
"      Dialysis modality and patient outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/28/2501?source=related_link\">",
"      Nonoliguric versus oliguric acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/51/18231?source=related_link\">",
"      Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4170?source=related_link\">",
"      Pathogenesis and etiology of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42154?source=related_link\">",
"      Possible prevention and therapy of postischemic (ischemic) acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17258?source=related_link\">",
"      Treatment and prevention of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36456?source=related_link\">",
"      Urine output and residual renal function in renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_37_4697="Medical management and indications for intervention in mitral stenosis";
var content_f4_37_4697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management and indications for intervention in mitral stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Matthew J Sorrentino, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4697/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/37/4697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral stenosis (MS) is due to thickening and immobility of the mitral valve leaflets, resulting in obstruction of blood flow from the left atrium to the left ventricle. The mechanical obstruction leads to increases in pressure within the left atrium, pulmonary vasculature, and right side of the heart. Although the left ventricle is unaffected in pure MS, mitral stenosis often coexists with mitral regurgitation and occasionally with aortic valve dysfunction, both of which can cause left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principal and often only symptom of MS is dyspnea due both to the reduced compliance of the lungs and to the decrease in vital capacity resulting from pulmonary vascular congestion and interstitial edema. Other symptoms may include hemoptysis (due to increased pulmonary pressures and vascular congestion), an embolic event, chest pain, and right-sided heart failure (with neck vein distention, edema, and hepatomegaly). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link\">",
"     \"Natural history of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progressive narrowing of the valve with the associated chronic elevations in left atrial and pulmonary venous pressures often results in significant dyspnea and not infrequently pulmonary edema. Over time, reactive changes in the pulmonary arterioles can lead to pulmonary hypertension and subsequent right-sided heart failure. Since MS is a mechanical disorder, its natural history is significantly altered, with an improvement in mortality, only by percutaneous mitral balloon valvotomy or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. However, pharmacologic therapy can provide significant symptomatic relief in patients who are awaiting intervention and in those with persistent symptoms after mechanical relief of valve obstruction. It also has an important role in managing and in some cases preventing the various complications of MS.",
"   </p>",
"   <p>",
"    The medical management and indications for intervention in MS will be reviewed here. Issues related to percutaneous mitral balloon valvotomy and surgery in such patients are discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EVALUATION AND FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timing of surgical or percutaneous intervention for MS is crucial for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If performed too early, the patient may be put at unnecessary risk for a complication of the procedure with little or no short-term benefit, since the MS may remain asymptomatic and stable for many years.",
"     </li>",
"     <li>",
"      Delaying intervention may cause irreversible pulmonary hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right heart failure. The risk of avoiding necessary corrective intervention was illustrated in a report that included patients in whom valve surgery was indicated but refused [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/4\">",
"       4",
"      </a>",
"      ]. Patient survival with medical therapy was 44 percent at five years, 32 percent at ten years, and 19 percent at 15 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among asymptomatic patients with mild MS (mitral valve area &gt;1.5 cm2 [normal 4 to 6 cm2]) in whom intervention is not indicated, yearly follow-up is recommended with history and physical examination. [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (AHA/AHA)",
"    </span>",
"    guidelines on the management of valvular heart disease suggest routine repeat echocardiography to assess pulmonary artery pressure in asymptomatic stable patients every year in those with severe MS, every one to two years with moderate MS, every three to five years with mild MS, and any time there is a change in clinical status (",
"    <a class=\"graphic graphic_table graphicRef68079 \" href=\"UTD.htm?39/25/40347\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3\">",
"     3",
"    </a>",
"    ]. The long interval between testing in asymptomatic, stable, mild disease is based in part upon the natural history of MS, as mitral valve area declines at a mean of about 0.1 cm2 per year. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=see_link&amp;anchor=H3#H3\">",
"     \"Natural history of mitral stenosis\", section on 'Loss of mitral valve area'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with significant MS are symptomatic with exertion, leading them to adopt a more sedentary lifestyle. However, all patients should be encouraged to participate in at least a low level exercise regimen to maintain cardiovascular fitness. Patients should be informed that sudden death in MS is extremely rare, which may alleviate certain fears about exercising.",
"   </p>",
"   <p>",
"    Each patient's exercise tolerance will vary depending upon the severity of their disease (",
"    <a class=\"graphic graphic_table graphicRef56145 \" href=\"UTD.htm?25/20/25931\">",
"     table 2",
"    </a>",
"    ) and the intensity and type of exercise (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/5\">",
"     5",
"    </a>",
"    ]. More specific recommendations for participation in competitive sports from the 36th Bethesda Conference are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in sinus rhythm with mild MS with peak pulmonary artery systolic pressures less than 50 mmHg can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Patients with moderate MS who are in sinus rhythm or atrial fibrillation (AF) and have peak pulmonary artery systolic pressures less than 50 mmHg can participate in low and moderate static and low and moderate dynamic competitive sports (class IA, IB, IIA, and IIB) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patients with severe MS who are in sinus rhythm or atrial fibrillation and patients with peak pulmonary artery systolic pressures greater than 50 mmHg should not participate in any competitive sports.",
"     </li>",
"     <li>",
"      Patients with MS of any severity who are in or have a history of AF and are treated with anticoagulation should not participate in any competitive sports associated with a risk of bodily contact or possible trauma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GENERAL USE OF PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of symptoms requiring medical therapy is an indication for intervention in patients with moderate to severe MS. Pharmacologic therapy is appropriate to improve loading conditions prior to intervention, for persistent symptoms after intervention, and for management of symptoms precipitated by an intercurrent illness or during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretic therapy (usually with a loop diuretic) plus dietary salt restriction are appropriate when there are manifestations of pulmonary vascular congestion such as exertional shortness of breath, orthopnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    paroxysmal nocturnal dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/7\">",
"     7",
"    </a>",
"    ]. At a later stage of MS, right-sided heart failure can occur, with hepatic congestion and peripheral edema. Loop diuretics acutely improve such manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pure MS may have modest reductions in left ventricular ejection fraction and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, symptoms suggesting left-sided heart failure are generally due to elevated left atrial and pulmonary pressures induced by the mechanical obstruction, not an impairment in left ventricular contractile function.",
"   </p>",
"   <p>",
"    Patients with MS who have left ventricular systolic dysfunction usually have concomitant mitral regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aortic valve disease. Right ventricular systolic dysfunction can also occur, due to left heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tricuspid regurgitation.",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in patients with MS who have symptomatic left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricular systolic dysfunction is similar to that in patients with other causes of systolic heart failure. Digoxin may also be helpful in controlling a rapid ventricular rate during AF, although it should not be considered a first-line drug for this indication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"     \"Use of digoxin in heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exertional symptoms are an indication for intervention. If exertional symptoms are greater than expected based on resting hemodynamics, an exercise stress study with measurement of pulmonary pressures at peak exercise is appropriate. However, when short-term medical therapy is needed in a decompensated patient with an intercurrent illness or in pregnant women, beta blockers can significantly decrease heart rate and cardiac output at rest, causing a decrease in the transmitral gradient, pulmonary capillary wedge pressure, and mean pulmonary pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, beta blockers can blunt the heart rate and cardiac output responses to exercise, thereby attenuating the rise in transmitral gradient that normally occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, despite the physiologic advantages of beta blockers in MS, it is not clear that these drugs improve exercise tolerance. Two crossover trials produced conflicting results: one showing no benefit from beta blocker therapy and the other suggesting improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A major limitation to the positive study was its single-blinded design, which can introduce bias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Secondary prevention of rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all cases of MS are the result of rheumatic involvement of the mitral valve. Although chronic degenerative changes associated with MS may represent a response to turbulent blood flow through the rheumatically deformed valve [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/14\">",
"     14",
"    </a>",
"    ], there is also evidence that repeated episodes of rheumatic carditis contribute to the natural history of MS even when no clinical signs of acute rheumatic fever have been present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Thus, preventing repeated attacks of rheumatic fever may play a role in delaying the progression of MS.",
"   </p>",
"   <p>",
"    The risk for recurrence of rheumatic fever declines with increasing age and the number of years since the patient's most recent attack and has been declining in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood of recurrence is positively correlated with an increased number of previous attacks and the presence and severity of preexisting rheumatic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/17\">",
"     17",
"    </a>",
"    ]. Recurrences of rheumatic fever tend to mimic previous attacks for any particular patient such that the absence of carditis during the initial attack usually means it will also not be a feature during future attacks.",
"   </p>",
"   <p>",
"    Patients with rheumatic MS should receive antibiotic prophylaxis for secondary prevention of rheumatic fever. Acceptable regimens and issues related to the duration of prophylaxis are discussed separately. Regardless of whether or not prophylaxis is continued, there should always be a low threshold to test and treat these patients for acute group A streptococcal pharyngitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"     \"Treatment and prevention of streptococcal tonsillopharyngitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevention of endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association guidelines on the prevention of bacterial endocarditis recommended that only patients with the highest risk of the development of endocarditis receive antimicrobial prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/18\">",
"     18",
"    </a>",
"    ]. Most patients with valvular heart disease, including those with mitral stenosis, are not included in this group and therefore no longer require antimicrobial prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention of thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic thromboembolism is a serious complication of MS, occurring in 13 to 26 percent of patients; it is most commonly associated with increasing age and the presence of AF [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/19-24\">",
"     19-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective study followed 534 patients with MS and a valve area of &le;2.0 cm2 for 37 months in an attempt to identify risk factors for embolism; 75 percent had atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Predictors of embolism in those in sinus rhythm included left atrial thrombus (relative risk 37), mitral valve area (relative risk 17), and the presence of significant aortic regurgitation (relative risk 22.4).",
"     </li>",
"     <li>",
"      Predictors of embolism in those in atrial fibrillation included previous embolism (relative risk 3), while percutaneous balloon valvotomy was a negative predictor (relative risk 0.37).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The association with left atrial thrombus and mitral valve area was not observed in older studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/21,24\">",
"     21,24",
"    </a>",
"    ]. Furthermore, in the above series, mitral valve area was no longer a significant predictor of systemic embolism when patients who had undergone percutaneous balloon mitral commissurotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors such as sex, functional class, left atrial pressure, mean pulmonary pressure, and transmitral gradient are not associated with an increased risk for thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/20,22\">",
"     20,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no randomized trials to determine the efficacy of long-term anticoagulation to prevent thromboembolism in patients with MS with or without an embolic event. A retrospective observational study suggested benefit when given for secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/22\">",
"     22",
"    </a>",
"    ], while the role of anticoagulation in patients with AF and no prior embolic events has been primarily supported by extrapolation of data from AF in patients without MS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These issues were better addressed in a substudy of the NASPEAF trial that included 311 patients with MS with and without prior embolism and 175 with nonvalvular AF and prior embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/26\">",
"     26",
"    </a>",
"    ]. The patients were randomly assigned to anticoagulation therapy (target INR 2.0 to 3.0, median attained value 2.5) or moderate intensity anticoagulation (INR 1.4 to 2.4, median attained value 2.2) in combination with the antiplatelet agent triflusal, which is structurally related to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The primary end point was a composite of fatal and nonfatal stroke and myocardial infarction, sudden death, or death from bleeding.",
"   </p>",
"   <p>",
"    The following findings were noted at a median follow-up of 2.9 years; a limitation is that the number of events was relatively small:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With anticoagulation therapy alone, the annual event rate in patients with MS was lower in those without a prior history of embolism (2.5 versus 6.6 percent with a history of embolism).",
"     </li>",
"     <li>",
"      Among patients with MS, combined therapy significantly lowered the annual event rate by 58 percent compared to anticoagulation; this effect was seen in patients with (3.5 versus 6.6 percent) and without (0.8 versus 2.5 percent) prior embolism.",
"     </li>",
"     <li>",
"      With equal therapy, the annual event rates in patients with prior embolism were similar in the patients with nonvalvular AF and MS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Antithrombotic recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally agree with the antithrombotic recommendations for mitral stenosis in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of valvular heart disease and the recommendations for rheumatic heart disease in the 2008 Eighth American College of Chest Physicians (ACCP) consensus conference which are detailed here [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,27\">",
"     3,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 2006",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      valvular disease guidelines and 2008 Eighth ACCP consensus conference recommended long-term oral anticoagulation (target INR 2.5, range 2.0 to 3.0) in patients with MS who have a prior embolic event, left atrial thrombus, or paroxysmal, persistent, or permanent AF, since all forms of AF carry a similar risk for thromboembolism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,27,28\">",
"       3,27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The ACCP consensus conference suggested the addition of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (50 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      in patients who have an embolic event or have left atrial thrombus despite oral anticoagulation at a therapeutic INR [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/27\">",
"       27",
"      </a>",
"      ]. An alternative strategy is to adjust the oral anticoagulant dose to achieve a higher target INR (target INR 3.0, range 2.5 to 3.5).",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines suggested that oral anticoagulation may be considered in patients with severe MS, an enlarged left atrium, and spontaneous echo contrast, although the evidence was less well established [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the evidence is somewhat limited and controversial, we suggest anticoagulation for patients with visualized spontaneous echo contrast in the left atrium. Support for this approach comes from a report of 168 patients with MS who underwent transesophageal echocardiography; 21 percent had a previous embolism and 46 percent were in atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/29\">",
"     29",
"    </a>",
"    ]. Multiple logistic regression analysis showed that AF, mitral valve area, and left atrial enlargement were independent predictors of spontaneous echo contrast, and left atrial spontaneous echo contrast was the principal determinant of thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=see_link\">",
"     \"Mechanisms of thrombogenesis in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One exception to our agreement with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    and 2008 ACCP guidelines is that we do not suggest anticoagulation for patients with mitral stenosis and left atrial diameter &ge;55 mm in the absence of another indication for anticoagulant therapy. Both guidelines suggested that, among patients with severe mitral stenosis without a prior embolic event or AF, long-term oral anticoagulation (target INR 2.5, range 2.0 to 3.0) may be considered if the left atrial diameter is &ge;55 mm, although supporting evidence was less well established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. In the ACCP guidelines, this suggestion applies to patients with left atrial diameter &gt;55 mm and any rheumatic mitral valve disease (not limited to those with severe mitral stenosis). This suggestion places a relatively high value on prevention of systemic embolism and a relatively low value on avoiding the bleeding risk and inconvenience associated with anticoagulation therapy.",
"   </p>",
"   <p>",
"    Newer oral anticoagulants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , now are approved for prevention of systemic embolism in adults with nonvalvular atrial fibrillation. We recommend use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in adults with mitral stenosis when oral anticoagulation is needed because patients with significant mitral valve disease were excluded from the trials of these newer agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Statin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective observational study found an association between treatment with statins and slower progression of rheumatic MS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/30\">",
"     30",
"    </a>",
"    ]. Of 315 patients with rheumatic MS, 35 patients were treated with statins and 280 were not. During follow-up (mean 6 years), the rates of decrease in mitral valve area and increase in mean transmitral gradient were lower in the statin group compared with the untreated group (0.027 versus 0.067",
"    <span class=\"nowrap\">",
"     cm2/y",
"    </span>",
"    and 0.20 versus 0.58",
"    <span class=\"nowrap\">",
"     mmHg/y).",
"    </span>",
"    An increase in pulmonary artery systolic pressure of &gt;10 mmHg was less common in the statin group compared with the untreated group (17 versus 40 percent). Further study in randomized controlled trials is required to determine whether statins have a beneficial impact in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF AF",
"    </span>",
"    &nbsp;&mdash;&nbsp;When MS is significant (valve area &lt;1.5 cm2), flow across the mitral valve is maintained by two factors: adequate diastolic filling time and higher-than-normal pulmonary capillary wedge pressure. Atrial fibrillation (AF) in patients with MS may be poorly tolerated for two reasons, with the hemodynamic consequences depending upon the severity of the stenosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The loss of atrial contraction results in decreased left ventricular filling; the resulting reduction in transmitral flow is more notable in MS because higher left atrial pressures are required to drive blood across the narrowed mitral orifice.",
"     </li>",
"     <li>",
"      If AF is associated with a rapid ventricular rate, the shortened diastolic filling time causes left atrial and pulmonary pressures to rise, potentially leading to pulmonary edema.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=see_link\">",
"     \"Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the medical management of AF for patients with MS does not significantly differ from general treatment guidelines. However, because of the exaggerated adverse hemodynamic effects caused by MS, prompt therapy is often necessary. In patients who are hemodynamically unstable, immediate electrical cardioversion is indicated. For hemodynamically stable patients, the initial management consists of controlling the ventricular rate (with a beta blocker without intrinsic sympathomimetic activity, calcium channel blocker [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ], or, less preferably,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ) and anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MS who have chronic AF have a stroke risk that may be as high as 7 to 15 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/31\">",
"     31",
"    </a>",
"    ]. As noted above, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines and the 2008 ACCP consensus conference recommended that, in patients with MS and AF,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    should be started and continued indefinitely to decrease the risk of systemic thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,27,28\">",
"     3,27,28",
"    </a>",
"    ]. The goal INR is 2.5 (range 2.0 to 3.0). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reversion to sinus rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rate control strategy is generally preferred because, based upon studies in patients with nonvalvular AF, outcomes are as good as or perhaps better than with a rhythm control strategy and, with a rhythm control strategy, long-term anticoagulation is still required in most patients. Nevertheless, conversion to sinus rhythm should be considered in patients with a contraindication to long-term anticoagulation and in those who are symptomatic with AF, have had previous thromboembolism despite adequate anticoagulation, or whose AF is of short duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=see_link\">",
"     \"Rhythm control versus rate control in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients in whom a rhythm control strategy is chosen, issues related to the method of restoration of sinus rhythm, anticoagulation before, during, and after cardioversion, and antiarrhythmic drug therapy to maintain sinus rhythm are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"     \"Restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=see_link\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the initial response to antiarrhythmic therapy, it may become increasingly difficult, if not impossible, to maintain sinus rhythm as the severity of MS progresses. For this reason, some physicians consider new onset AF to be an early marker of adverse hemodynamic effects of MS on the left atrium; as a result, they consider AF to be an indication for percutaneous balloon valvotomy, even in an otherwise asymptomatic patient with only moderate MS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to prevention of recurrent AF is radiofrequency ablation (RFA). RFA has been increasingly studied in patients without structural heart disease, but its role in those with rheumatic heart disease is uncertain. In one report, electrophysiologic mapping was performed in 17 patients with MS who had chronic AF and were reverted to sinus rhythm after balloon valvulotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/32\">",
"     32",
"    </a>",
"    ]. An organized atrial arrhythmia, which degenerated into AF, was induced in all patients; the focus was most often near the coronary sinus ostium. Radiofrequency ablation was successful in 13 and, after a mean follow-up of 32 weeks, 10 were still in sinus rhythm.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines on AF concluded that catheter ablation is a reasonable alternative to pharmacologic therapy for the prevention recurrent AF in symptomatic patients with little or no left atrial enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/33\">",
"     33",
"    </a>",
"    ]. The presence of left atrial enlargement would exclude many patients with MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal pregnancy is associated with hemodynamic changes that may be poorly tolerated in women with MS, particularly in those with more advanced disease. In comparison, pregnant women with mild to moderate MS can usually be managed medically without difficulty. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=see_link\">",
"     \"Pregnancy in women with mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR INTERVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since MS is a mechanical disorder, its natural history is significantly altered, with an improvement in mortality, only by intervention by percutaneous mitral balloon valvotomy or surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Issues related to percutaneous mitral balloon valvotomy and surgery in patients with MS are discussed separately. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines with 2008 focused update and the 2007 European Society of Cardiology (ESC) guidelines on the management of valvular heart disease concluded that the primary indications for intervention were moderate to severe MS and the presence of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. The main indication for intervention in asymptomatic patients was moderate to severe MS and pulmonary hypertension (pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise) (",
"    <a class=\"graphic graphic_algorithm graphicRef70612 \" href=\"UTD.htm?20/38/21103\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Exercise stress echocardiography may be helpful when symptoms seem to be more severe than expected based upon resting hemodynamics (such as the resting mitral valve area); these patients often have exertional pulmonary hypertension (",
"    <a class=\"graphic graphic_algorithm graphicRef70612 \" href=\"UTD.htm?20/38/21103\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=see_link&amp;anchor=H17#H17\">",
"     \"Protocols for stress echocardiography\", section on 'Mitral stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography also may help determine whether corrective intervention is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/35\">",
"     35",
"    </a>",
"    ]. In a series of 53 patients with known MS, the diastolic mitral gradient during dobutamine stress was a significant predictor of clinical events (arrhythmias or hospitalization for dyspnea or pulmonary edema) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4697/abstract/36\">",
"     36",
"    </a>",
"    ]. At a cutoff gradient of 18 mmHg, dobutamine stress had a sensitivity of 90 percent and a specificity of 87 percent for predicting clinical events during five year mean follow-up. However, this approach requires further validation; dobutamine stress echocardiography is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for routine evaluation of patients with MS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link&amp;anchor=H11#H11\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Stress echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=see_link\">",
"       \"Patient information: Mitral stenosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6360118\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitral stenosis (MS) secondary to rheumatic heart disease leads to thickening and immobility of the valve leaflets resulting in obstruction of blood flow from the left atrium to the left ventricle. The mechanical obstruction leads to increases in pressure within the left atrium, pulmonary vasculature, and right side of the heart. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since MS is a mechanical disorder, its natural history is significantly altered, with an improvement in mortality, only by percutaneous mitral balloon valvotomy or surgery. Medical management strategies should be viewed as adjunctive to either percutaneous or surgical intervention when intervention is warranted. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of surgical or percutaneous intervention for MS is crucial to avoid the risk of unnecessarily early intervention as well as the risk of irreversible pulmonary hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      right heart failure from delaying necessary intervention. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine repeat echocardiography to assess pulmonary artery pressure is suggested in asymptomatic stable patients every year in those with severe MS, every one to two years with moderate MS, every three to five years with mild MS, and any time there is a change in clinical status (",
"      <a class=\"graphic graphic_table graphicRef68079 \" href=\"UTD.htm?39/25/40347\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Evaluation and follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic therapy is only appropriate as stabilization prior to intervention, to treat decompensation due to an intercurrent illness or for persistent symptoms after intervention. In these settings, diuretics and beta blockers may improve symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Beta blockers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with rheumatic MS should receive antibiotic prophylaxis for secondary prevention of rheumatic fever. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Secondary prevention of rheumatic fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend long-term oral anticoagulation (target INR 2.5, range 2.0 to 3.0) in patients with MS who have a prior embolic event, left atrial thrombus, or paroxysmal, persistent, or permanent AF. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antithrombotic recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest oral anticoagulation is patients with visualized spontaneous echo contrast in the left atrium. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antithrombotic recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the medical management of AF for patients with MS does not significantly differ from general treatment guidelines. However, because of the exaggerated adverse hemodynamic effects caused by MS, prompt therapy is often necessary. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Management of AF'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intervention by percutaneous mitral balloon valvotomy or surgery is indicated in patients with moderate to severe MS with symptoms. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Indications for intervention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The main indication for intervention in asymptomatic patients is moderate to severe MS and pulmonary hypertension (pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise) (",
"      <a class=\"graphic graphic_algorithm graphicRef70612 \" href=\"UTD.htm?20/38/21103\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Indications for intervention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/1\">",
"      Ellis LB, Singh JB, Morales DD, Harken DE. Fifteen-to twenty-year study of one thousand patients undergoing closed mitral valvuloplasty. Circulation 1973; 48:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/2\">",
"      Orrange SE, Kawanishi DT, Lopez BM, et al. Actuarial outcome after catheter balloon commissurotomy in patients with mitral stenosis. Circulation 1997; 95:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/3\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/4\">",
"      Horstkotte D, Niehues R, Strauer BE. Pathomorphological aspects, aetiology and natural history of acquired mitral valve stenosis. Eur Heart J 1991; 12 Suppl B:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/5\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/6\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/7\">",
"      Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol 1998; 23:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/8\">",
"      Austin SM, Schreiner BF, Kramer DH, et al. The acute hemodynamic effects of ethacrynic acid and furosemide in patients with chronic postcapillary pulmonary hypertension. Circulation 1976; 53:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/9\">",
"      Toutouzas P. Left ventricular function in mitral valve disease. Herz 1984; 9:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/10\">",
"      Gaasch WH, Folland ED. Left ventricular function in rheumatic mitral stenosis. Eur Heart J 1991; 12 Suppl B:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/11\">",
"      Meister SG, Engel TR, Feitosa GS, et al. Propranolol in mitral stenosis during sinus rhythm. Am Heart J 1977; 94:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/12\">",
"      Stoll BC, Ashcom TL, Johns JP, et al. Effects of atenolol on rest and exercise hemodynamics in patients with mitral stenosis. Am J Cardiol 1995; 75:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/13\">",
"      Klein HO, Sareli P, Schamroth CL, et al. Effects of atenolol on exercise capacity in patients with mitral stenosis with sinus rhythm. Am J Cardiol 1985; 56:598.",
"     </a>",
"    </li>",
"    <li>",
"     Stapleton JF. Natural history of chronic valvular disease. In: Cardiovascular Clinics. Valvular heart disease: comprehensive evaluation and management, Frankl WS, Brest AN (Eds), FA Davis, Philadelphia 1986. p.128.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/15\">",
"      Edwards WD, Peterson K, Edwards JE. Active valvulitis associated with chronic rheumatic valvular disease and active myocarditis. Circulation 1978; 57:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/16\">",
"      Clawson, BJ. Rheumatic heart disease. An analysis of 796 cases. Am Heart J 1940; 20:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/17\">",
"      Dickinson GM, Bisno AL. Antimicrobial prophylaxis of infection. Infect Dis Clin North Am 1995; 9:783.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/19\">",
"      Chiang CW, Lo SK, Ko YS, et al. Predictors of systemic embolism in patients with mitral stenosis. A prospective study. Ann Intern Med 1998; 128:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/20\">",
"      CASELLA L, ABELMANN WH, ELLIS LB. PATIENTS WITH MITRAL STENOSIS AND SYSTEMIC EMBOLI; HEMODYNAMIC AND CLINICAL OBSERVATIONS. Arch Intern Med 1964; 114:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/21\">",
"      Coulshed N, Epstein EJ, McKendrick CS, et al. Systemic embolism in mitral valve disease. Br Heart J 1970; 32:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/22\">",
"      Abernathy WS, Willis PW 3rd. Thromboembolic complications of rheumatic heart disease. Cardiovasc Clin 1973; 5:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/23\">",
"      ROWE JC, BLAND EF, SPRAGUE HB, WHITE PD. The course of mitral stenosis without surgery: ten- and twenty-year perspectives. Ann Intern Med 1960; 52:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/24\">",
"      WOOD P. An appreciation of mitral stenosis. I. Clinical features. Br Med J 1954; 1:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/25\">",
"      Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999; 131:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/26\">",
"      P&eacute;rez-G&oacute;mez F, Salvador A, Zumalde J, et al. Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: a sub-analysis of NASPEAF randomized trial. Eur Heart J 2006; 27:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/27\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/28\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/29\">",
"      Acart&uuml;rk E, Usal A, Demir M, et al. Thromboembolism risk in patients with mitral stenosis. Jpn Heart J 1997; 38:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/30\">",
"      Antonini-Canterin F, Moura LM, Enache R, et al. Effect of hydroxymethylglutaryl coenzyme-a reductase inhibitors on the long-term progression of rheumatic mitral valve disease. Circulation 2010; 121:2130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/31\">",
"      Carabello BA. Modern management of mitral stenosis. Circulation 2005; 112:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/32\">",
"      Nair M, Shah P, Batra R, et al. Chronic atrial fibrillation in patients with rheumatic heart disease: mapping and radiofrequency ablation of flutter circuits seen at initiation after cardioversion. Circulation 2001; 104:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/33\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/34\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/35\">",
"      Cheitlin MD. Stress echocardiography in mitral stenosis: when is it useful? J Am Coll Cardiol 2004; 43:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4697/abstract/36\">",
"      Reis G, Motta MS, Barbosa MM, et al. Dobutamine stress echocardiography for noninvasive assessment and risk stratification of patients with rheumatic mitral stenosis. J Am Coll Cardiol 2004; 43:393.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8139 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-3011E4F32C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4697=[""].join("\n");
var outline_f4_37_4697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6360118\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EVALUATION AND FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSICAL ACTIVITY AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GENERAL USE OF PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Digoxin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Secondary prevention of rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevention of endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention of thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Antithrombotic recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Statin therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT OF AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INDICATIONS FOR INTERVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6360118\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8139|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/38/21103\" title=\"algorithm 1\">",
"      Management asymptomatic MS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8139|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 1\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/25/40347\" title=\"table 1\">",
"      Echo in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/20/25931\" title=\"table 2\">",
"      Severity of MS in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20938?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/28/6601?source=related_link\">",
"      Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43528?source=related_link\">",
"      Mechanisms of thrombogenesis in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/29/18901?source=related_link\">",
"      Natural history of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/31/12787?source=related_link\">",
"      Patient information: Mitral stenosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29447?source=related_link\">",
"      Pregnancy in women with mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35319?source=related_link\">",
"      Protocols for stress echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=related_link\">",
"      Surgical management of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=related_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_37_4698="Terminology, epidemiology, and pathogenesis of autism spectrum disorders";
var content_f4_37_4698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Terminology, epidemiology, and pathogenesis of autism spectrum disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Carolyn Bridgemohan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/37/4698/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/37/4698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) categorizes these disorders under \"pervasive developmental disorders\" (PDD) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1\">",
"     1",
"    </a>",
"    ]. These disorders include autistic disorder (classic autism, sometimes called early infantile autism, childhood autism, or Kanner's autism), Rett disorder, childhood disintegrative disorder, Asperger disorder (also known as Asperger syndrome), and pervasive developmental disorder-not otherwise specified (PDD-NOS), including atypical autism.",
"   </p>",
"   <p>",
"    The terminology, epidemiology, and pathogenesis of ASD will be reviewed here. The arrival of the DSM V is highly anticipated and will potentially change the current rubric [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/2\">",
"     2",
"    </a>",
"    ]. Surveillance and screening, clinical features, diagnosis, and management of ASD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link\">",
"     \"Clinical features of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=see_link\">",
"     \"Diagnosis of autism spectrum disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=see_link\">",
"     \"Autism spectrum disorders in children and adolescents: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"pervasive developmental disorders\" (PDD) and \"autism spectrum disorders\" (ASD) describe a heterogeneous group of neurodevelopmental disorders that have diverse etiologies but are characterized by constellations of symptoms involving reciprocal social interaction, communication, and behavior (specifically stereotyped interests and activities) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. This group of disorders includes autistic disorder, Rett disorder, childhood disintegrative disorder, Asperger disorder, and pervasive developmental disorder-not otherwise specified (PDD-NOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Rett disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"     \"Rett syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Autistic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) provides specific criteria to diagnose autistic disorder (",
"    <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1\">",
"     1",
"    </a>",
"    ]. High-functioning autism is the term used to describe individuals with intelligence quotient (IQ) &gt;70 (ie, borderline and above intelligence) who have the core features of autism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rett disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rett disorder is a neurodevelopmental disorder that occurs almost exclusively in females. Affected patients initially develop normally, then gradually lose speech and purposeful hand use sometime after 18 months of age. Most cases of Rett syndrome result from mutations in the",
"    <em>",
"     MECP2",
"    </em>",
"    gene. Characteristic features of Rett syndrome include deceleration of head growth (in contrast to acceleration of head growth, which occurs in other ASD), stereotypic hand movements, and dementia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link&amp;anchor=H7#H7\">",
"     \"Rett syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Childhood disintegrative disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The essential feature of childhood disintegrative disorder (CDD), which is extremely rare, is a marked regression in multiple areas of functioning following a period of at least two years of apparently normal development. Apparently normal development is reflected in age-appropriate verbal and nonverbal communication, social relationships, play, and adaptive behavior. After the first two years of life (but before age 10 years), the child has a clinically significant loss of previously acquired skills in at least two of the following areas: expressive or receptive language, social skills or adaptive behavior, bowel or bladder control, play, or motor skills. Children with CDD are essentially identical to children with autistic disorder, save a history of normal development. CDD is often associated with an identified organic condition (eg, seizures, metabolic disorder, etc).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Asperger disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR provides specific criteria to diagnose Asperger disorder (",
"    <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to autistic disorder, individuals with Asperger disorder have better facility with the mechanics of verbal expression, higher levels of cognitive function, and greater interest in interpersonal social activity (often around their current obsessive preoccupation) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. There is some controversy regarding whether Asperger disorder is a form of high-functioning autism or a separate disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15689?source=see_link\">",
"     \"Asperger disorder: Clinical features and diagnosis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    What distinguishes children with high-functioning autism from those with Asperger disorder is the lack of clinically significant delays or deviance in language acquisition in children with Asperger disorder, although more subtle aspects of social communication may be affected. As examples, children with Asperger disorder may use single non-echoed words communicatively by age two years and communicative phrases by age three years, but have difficulty with the typical give-and-take in conversation. In addition, children with Asperger disorder lack clinically significant delays in cognitive development or in the acquisition of age-appropriate learning skills and adaptive behaviors (other than social interaction) during the first three years of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     PDD-not otherwise specified",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"PDD-NOS\" is used to describe individuals who meet some, but not all, of the DSM-IV-TR criteria for autistic disorder (ie, atypical autism) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Individuals may fall into this category because of late age of presentation, atypical symptoms, or subthreshold symptoms. In addition, some clinicians make an initial diagnosis of PDD-NOS in children younger than 36 months regardless of the number or severity of symptoms because diagnostic accuracy is lower in younger children. There is significant discussion about the utility of this category of individuals and need for further clarification [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autism spectrum disorders (ASD) are approximately four times more common in males than females [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1,9-14\">",
"     1,9-14",
"    </a>",
"    ]. Estimates of prevalence vary depending upon the study methodology and the population that is evaluated.",
"   </p>",
"   <p>",
"    The prevalence of ASD in the United States and other countries has increased since the 1970s, and particularly since the late 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/15\">",
"     15",
"    </a>",
"    ]. The majority of studies conducted from the mid-1990s indicate a prevalence of approximately 1 in 1000 for autism and 2 in 1000 for ASD, compared with 0.4 to 0.5 per 1000 in previous decades [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/15\">",
"     15",
"    </a>",
"    ]. However, more recent studies in Europe, Asia, and the United States indicate that the prevalence of ASD ranges from 2 to 20 per 1000, or approximately 1 in 50 to 1 in 500 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/9,10,13,14,16-26\">",
"     9,10,13,14,16-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2011-2012 National Survey of Children&rsquo;s Health, a nationally representative telephone survey, the prevalence of parent-reported ASD among children 6 to 17 years of age was 20 per 1000 (1 in 50), an increase from 2007 (approximately 11 per 1000) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/14\">",
"     14",
"    </a>",
"    ]. The increase was driven by new diagnoses, predominantly among children age 6 to 13 years. A major limitation of this study is the lack of substantiation of parents&rsquo; reports. However, the 2007 prevalence was similar to that estimated by the Autism and Developmental Disabilities Monitoring (ADDM) Network, in which ASDs were identified through screening and abstraction of existing health and education records that documented behaviors consistent with the DSM-IV criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/13,27\">",
"     13,27",
"    </a>",
"    ]. ADDM data indicated an overall prevalence of 9 per 1000 at age eight years for 2006 and 11 per 1000 at age eight years for 2008 (approximately 1 in 54 boys and 1 in 252 girls). The prevalence estimates varied widely by site, sex, and",
"    <span class=\"nowrap\">",
"     racial/ethnic",
"    </span>",
"    group [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a controversial study that used a novel approach of case finding, the prevalence appeared to be higher. A population-based study of children (ages 7 to 12 years) from special education and regular schools in Korea estimated the prevalence to be 1 in 38 (2.64 percent), with two-thirds of the cases identified in children from the regular schools [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/28\">",
"     28",
"    </a>",
"    ]. However, the methodology of this study complicates its generalizability due to both cultural confounders and lower screening criteria, thus &ldquo;casting a broader net&rdquo; in the general population, which had a less-than-optimal participation rate (63 percent). These findings require replication in other populations, as well as refinement of the criteria used.",
"   </p>",
"   <p>",
"    Although there are increasing numbers of children diagnosed with ASD, it is not clear whether the increase is related to changes in diagnostic criteria, study methodology, a true increase in the incidence of autism, or a combination of these factors. Comparing studies with different case definitions, methods of case finding, and sample populations is problematic unless there is rigorous control for these variables, even when the studies being compared occur during the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systematic reviews of the epidemiologic studies of autism have found evidence that changes in case definition and increased awareness account for much of the apparent increase in the prevalence of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/9,15,29,30\">",
"     9,15,29,30",
"    </a>",
"    ]. Other factors that may play a role include earlier detection, availability of more specialized developmental services, and diagnostic substitution (ie, increases in prevalence of autism accompanied by decreases in the prevalence of learning disorders, developmental language disorder,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mental retardation [intellectual disability]) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/9,30-36\">",
"     9,30-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Rate in siblings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of ASD without associated medical conditions in siblings of children with ASD has been estimated to range from 2 to 8 percent based on studies with methodologic limitations (small sample size, ascertainment bias, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/37-44\">",
"     37-44",
"    </a>",
"    ]. However, in one longitudinal prospective study, 18.7 percent of infants who had an older sibling with ASD developed ASD by age 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Associated conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of conditions associated with autism. Mental retardation (intellectual disability) was present in approximately 75 percent of cases in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/45\">",
"     45",
"    </a>",
"    ]. Studies since 2000 have shown rates between 45 and 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. Seizures also occur in 11 to 39 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,46-51\">",
"     3,46-51",
"    </a>",
"    ]. The risk of seizures is higher in individuals with more severe intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A minority (fewer than 10 to 25 percent) of cases of ASD are associated with a medical condition or known syndrome (eg, phenylketonuria, fetal alcohol syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,17,52-55\">",
"     3,17,52-55",
"    </a>",
"    ]. Associated medical conditions are more common in patients with comorbid global developmental delay or intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common associated genetic disorders include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,46,56\">",
"     3,46,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberous sclerosis complex &ndash; 17 to 60 percent of patients with tuberous sclerosis complex are also autistic; however, only 0.4 to 4 percent of patients with autism have tuberous sclerosis complex [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/57-59\">",
"       57-59",
"      </a>",
"      ]. Patients with comorbid tuberous sclerosis complex and autism often have epilepsy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/57,59-61\">",
"       57,59-61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"       \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fragile X &ndash; As many as 30 to 50 percent of patients with fragile X syndrome have features of autism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,62,63\">",
"       3,62,63",
"      </a>",
"      ]. However, with cytogenetic techniques (not DNA analysis) and molecular analysis, fragile X syndrome is rarely found in patients with autism [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"       \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      15q chromosome",
"      <span class=\"nowrap\">",
"       duplications/triplications",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/46,66,67\">",
"       46,66,67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      15q deletions (ie, Angelman syndrome) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic factors'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Rett syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=see_link\">",
"       \"Rett syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smith-Lemli-Opitz syndrome &ndash; Smith-Lemli-Opitz syndrome is an autosomal recessive disorder of cholesterol biosynthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3\">",
"       3",
"      </a>",
"      ]. Clinical features include post-natal microcephaly, soft cleft",
"      <span class=\"nowrap\">",
"       palate/bifid",
"      </span>",
"      uvula, micrognathia, low-set posteriorly rotated ears, failure to thrive, syndactyly of the second and third toes, abnormal genitalia, intellectual disability, hypotonia, and autistic features [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/68,69\">",
"       68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others &ndash; Other chromosomal \"hot spots\" include chromosome X, 2, 3, 7q, 17, and 22q. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genetic factors'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160246736\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of autism spectrum disorders (ASD) is incompletely understood. The general consensus is that ASD has a genetic etiology, which alters brain development, affecting social and communication development and leading to restricted interests and repetitive behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38,70\">",
"     38,70",
"    </a>",
"    ]. Supporting this is the \"epigenetic theory\", in which an abnormal gene is turned \"on\" early in fetal development and affects the expression of other genes that are not mutated themselves [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing evidence for the role of genetic factors in the etiology of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,38,46\">",
"     3,38,46",
"    </a>",
"    ]. Evidence for the strong genetic contribution to development of ASD is derived from the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unequal sex distribution, with 4:1 male predominance [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased prevalence in siblings of patients with ASD compared with the general population (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Rate in siblings'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      High concordance rate among monozygotic twins (36 to 96 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/73-78\">",
"       73-78",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the complexity of ASD and the diversity of clinical manifestations, it is likely that interactions between multiple genes are responsible for ASD and that epigenetic factors and exposure to environmental modifiers contribute to the variable expression [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38,78,79\">",
"     38,78,79",
"    </a>",
"    ]. The wide phenotypic variability also suggests the existence of distinct genes and gene combinations among those who are affected [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38\">",
"     38",
"    </a>",
"    ]. Another possibility is that ASD are caused by variations in copy number (resulting from spontaneous deletion or duplication during gamete production) at multiple independent loci [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. This hypothesis is supported by the observation that deletion or duplication at 15 q11.2 and 16p11.2 accounts for 2 to 3 percent of cases of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/85-88\">",
"     85-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence among siblings of patients with ASD is higher than the prevalence in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38-41\">",
"     38-41",
"    </a>",
"    ], but much lower than would be expected for single-gene diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38\">",
"     38",
"    </a>",
"    ]. Although male predominance suggests X-linkage, male-to-male transmission in a number of families excludes X-linkage as the only mode of inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38,89\">",
"     38,89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Rate in siblings'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevalence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Current research is focused on linkage studies in families to sort out the complex multigenic nature of ASD. Several ongoing studies are investigating the correlation of clinical phenotypes with specific genetic profiles.",
"   </p>",
"   <p>",
"    Thus far, linkage studies and genomic screens have identified several potential loci for autism susceptibility on multiple chromosomes, including the X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/38,66,87,90-98\">",
"     38,66,87,90-98",
"    </a>",
"    ]. A duplication in the proximal long arm of chromosome 15 (15q11-q13) has been reported in approximately 1 to 2 percent of autistic children, usually those with moderate to profound intellectual disability [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/46,85,86,88,99\">",
"     46,85,86,88,99",
"    </a>",
"    ]. The duplication is usually maternally inherited, with one or two copies of the area roughly corresponding to the typical Angelman",
"    <span class=\"nowrap\">",
"     syndrome/Prader-Willi",
"    </span>",
"    deletion region. A \"chromosome 15 phenotype\" has begun to emerge that is characterized by hypotonia, joint laxity, global (especially motor) developmental delays, seizures, speech delay, social deficits, stereotypies, and a variable pattern of mild facial dysmorphisms [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=see_link\">",
"     \"Epidemiology and genetics of Prader-Willi syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with autism spectrum disorders and macrocephaly are at increased risk for",
"    <em>",
"     PTEN",
"    </em>",
"    mutations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link&amp;anchor=H462460064#H462460064\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\", section on 'Autism spectrum disorders and macrocephaly'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other potential loci are close to known locations of a gene for tuberous sclerosis complex (chromosome 16p) or neurofibromatosis type 1 (chromosome 17) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/87,101\">",
"     87,101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=see_link\">",
"     \"Tuberous sclerosis complex: Genetics, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neurobiologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroimaging and autopsy studies in patients with autism suggest that brain abnormalities play an important role [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/90,102\">",
"     90,102",
"    </a>",
"    ]. These abnormalities include diffuse differences in total and regional gray and white matter volumes, sulcal and gyral anatomy, brain chemical concentrations, neural networks, brain lateralization, and cognitive processing compared with individuals without autism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/103-109\">",
"     103-109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for brain abnormalities is derived from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with autism have accelerated head growth during infancy and increased overall brain size (by 2 to 10 percent), perhaps related to an increased number of neurons in the prefrontal cortex [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/110-112\">",
"       110-112",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical features of autism spectrum disorders\", section on 'Macrocephaly'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Functional MRI studies indicate that individuals with ASD use different patterns of connectivity, cognitive strategies, and brain areas to process information during tasks requiring social attribution or response to visual or auditory stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/113-122\">",
"       113-122",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Positron emission tomography studies have shown that children with autism have global and functional abnormalities in serotonin synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/123\">",
"       123",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Brain electrophysiology studies indicate that individuals with ASD process information regarding faces differently [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/124,125\">",
"       124,125",
"      </a>",
"      ] and appear to have marked delay in the neural system processing eye gaze [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/126\">",
"       126",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Individuals with ASD appear to have neural-based deficits in recognizing and understanding speech and attending to socially relevant sounds [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/127-130\">",
"       127-130",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neuropathologic studies demonstrate decreased numbers of Purkinje cells in the cerebellum (which modulates a variety of brain functions and impacts language processing, anticipatory and motor planning, mental imagery, and timed sequencing) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/131\">",
"       131",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2160246807\">",
"    <span class=\"h2\">",
"     Environmental and perinatal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors, such as toxic exposures, teratogens, perinatal insults, and prenatal infections, account for few cases. A meta-analysis of 40 heterogeneous studies of perinatal and neonatal risk factors for autism found little evidence to implicate any single factor in the etiology of autism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/132\">",
"     132",
"    </a>",
"    ]. However there was some evidence to suggest that the broad class of conditions that compromise perinatal and neonatal health (eg, abnormal presentation, low birth weight, meconium aspiration, etc) may increase the risk. As an example, in one prospective study of a regional birth cohort of infants weighing &lt;2000 g at birth, the prevalence of ASD (5 percent) was approximately five times the rate in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/133\">",
"     133",
"    </a>",
"    ]. In another population-based study, maternal metabolic conditions (eg, diabetes, obesity, hypertension) were associated with an increased risk of ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Environmental factors may constitute a \"second-hit\", modulating existing genetic factors predisposing to ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/3,38\">",
"     3,38",
"    </a>",
"    ]. The effects of environmental exposures appear to depend on the timing and duration of exposure, concentration of the toxin, mechanism of action, and distribution in the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Parental age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced parental age (both paternal and maternal) has been associated with an increased risk of having a child with ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/135-141\">",
"     135-141",
"    </a>",
"    ]. This is perhaps related to de novo spontaneous mutations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alterations in genetic imprinting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/37/4698/abstract/142\">",
"     142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=see_link&amp;anchor=H1497302#H1497302\">",
"     \"Basic principles of genetic disease\", section on 'Imprinting'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Lack of association with immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have attributed regressive autism to vaccine exposure (particularly measles vaccine and thimerosal (a mercury preservative used in vaccines)). However, the overwhelming majority of epidemiologic evidence does not support an association between immunizations and autism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=see_link\">",
"       \"Patient information: Autism spectrum disorders (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autism spectrum disorders (ASD) are a group of biologically based neurodevelopmental disorders characterized by impairments in three major domains: socialization, communication, and behavior. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ASD include autistic disorder (",
"      <a class=\"graphic graphic_table graphicRef72403 \" href=\"UTD.htm?29/6/29804\">",
"       table 1",
"      </a>",
"      ), pervasive developmental disorder-not otherwise specified (PDD-NOS), and Asperger disorder (",
"      <a class=\"graphic graphic_table graphicRef60599 \" href=\"UTD.htm?12/57/13212\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various studies have shown a wide range of potential prevalence, from a low of 1 in 500 to a high of 1 in 50. Further definitive investigation and diagnostic clarification may clarify this broad range in the future. The prevalence of ASD in the United States and other countries appears to have increased since the 1970s, primarily as a result of changes in case definition and increased awareness. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Intellectual disability and seizures are common in children with ASD. ASD is more common among children with certain genetic conditions than in the general population. These conditions include tuberous sclerosis complex, fragile X syndrome, 15q",
"      <span class=\"nowrap\">",
"       duplication/triplication",
"      </span>",
"      or deletion, Smith-Lemli-Opitz syndrome, and untreated phenylketonuria. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Associated conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis of ASD is incompletely understood. The general consensus is that ASD have a genetic etiology, which leads to altered brain development, resulting in the neurobehavioral phenotype. Epidemiologic studies indicate that environmental factors account for few cases. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overwhelming majority of epidemiologic evidence does not support an association between immunizations and autism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link\">",
"       \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"       \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Pervasive Developmental Disorders. In: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000. p.70.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/2\">",
"      Wing L, Gould J, Gillberg C. Autism spectrum disorders in the DSM-V: better or worse than the DSM-IV? Res Dev Disabil 2011; 32:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/3\">",
"      Johnson CP, Myers SM, American Academy of Pediatrics Council on Children With Disabilities. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007; 120:1183.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Mental Health. Autism spectrum disorders (pervasive developmental disorders). file://www.nimh.nih.gov/health/publications/autism/complete-index.shtml (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     Volkman F, Wiesner L. Autism and related disorders. In: Developmental-Behavioral Pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.675.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/6\">",
"      Sharma S, Woolfson LM, Hunter SC. Confusion and inconsistency in diagnosis of Asperger syndrome: a review of studies from 1981 to 2010. Autism 2012; 16:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/7\">",
"      Mandy W, Charman T, Gilmour J, Skuse D. Toward specifying pervasive developmental disorder-not otherwise specified. Autism Res 2011; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/8\">",
"      Walker DR, Thompson A, Zwaigenbaum L, et al. Specifying PDD-NOS: a comparison of PDD-NOS, Asperger syndrome, and autism. J Am Acad Child Adolesc Psychiatry 2004; 43:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/9\">",
"      Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009; 65:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). Mental health in the United States: parental report of diagnosed autism in children aged 4-17 years--United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006; 55:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/11\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, six sites, United States, 2000. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/12\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2002 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, 14 sites, United States, 2002. MMWR Surveill Summ 2007; 56:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/13\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     Blumberg SJ, Bramlett MD, Kogan MD, et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged U.S. children: 2007 to 2011-2012. file://www.cdc.gov/nchs/data/nhsr/nhsr065.pdf (Accessed on March 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/15\">",
"      Williams JG, Higgins JP, Brayne CE. Systematic review of prevalence studies of autism spectrum disorders. Arch Dis Child 2006; 91:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/16\">",
"      Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 2006; 368:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/17\">",
"      Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children. JAMA 2001; 285:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/18\">",
"      Bertrand J, Mars A, Boyle C, et al. Prevalence of autism in a United States population: the Brick Township, New Jersey, investigation. Pediatrics 2001; 108:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/19\">",
"      Gurney JG, Fritz MS, Ness KK, et al. Analysis of prevalence trends of autism spectrum disorder in Minnesota. Arch Pediatr Adolesc Med 2003; 157:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/20\">",
"      Webb E, Morey J, Thompsen W, et al. Prevalence of autistic spectrum disorder in children attending mainstream schools in a Welsh education authority. Dev Med Child Neurol 2003; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/21\">",
"      Harrison MJ, O'Hare AE, Campbell H, et al. Prevalence of autistic spectrum disorders in Lothian, Scotland: an estimate using the \"capture-recapture\" technique. Arch Dis Child 2006; 91:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/22\">",
"      Williams E, Thomas K, Sidebotham H, Emond A. Prevalence and characteristics of autistic spectrum disorders in the ALSPAC cohort. Dev Med Child Neurol 2008; 50:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/23\">",
"      Kogan MD, Blumberg SJ, Schieve LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics 2009; 124:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/24\">",
"      Manning SE, Davin CA, Barfield WD, et al. Early diagnoses of autism spectrum disorders in Massachusetts birth cohorts, 2001-2005. Pediatrics 2011; 127:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/25\">",
"      Chien IC, Lin CH, Chou YJ, Chou P. Prevalence and incidence of autism spectrum disorders among national health insurance enrollees in Taiwan from 1996 to 2005. J Child Neurol 2011; 26:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/26\">",
"      Sur&eacute;n P, Bakken IJ, Aase H, et al. Autism spectrum disorder, ADHD, epilepsy, and cerebral palsy in Norwegian children. Pediatrics 2012; 130:e152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/27\">",
"      Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorders - Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/28\">",
"      Kim YS, Leventhal BL, Koh YJ, et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry 2011; 168:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/29\">",
"      Wing L, Potter D. The epidemiology of autistic spectrum disorders: is the prevalence rising? Ment Retard Dev Disabil Res Rev 2002; 8:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/30\">",
"      Shattuck PT. The contribution of diagnostic substitution to the growing administrative prevalence of autism in US special education. Pediatrics 2006; 117:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/31\">",
"      Croen LA, Grether JK, Hoogstrate J, Selvin S. The changing prevalence of autism in California. J Autism Dev Disord 2002; 32:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/32\">",
"      Barbaresi WJ, Katusic SK, Colligan RC, et al. The incidence of autism in Olmsted County, Minnesota, 1976-1997: results from a population-based study. Arch Pediatr Adolesc Med 2005; 159:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/33\">",
"      Mandell DS, Palmer R. Differences among states in the identification of autistic spectrum disorders. Arch Pediatr Adolesc Med 2005; 159:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/34\">",
"      Bishop DV, Whitehouse AJ, Watt HJ, Line EA. Autism and diagnostic substitution: evidence from a study of adults with a history of developmental language disorder. Dev Med Child Neurol 2008; 50:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/35\">",
"      Parner ET, Schendel DE, Thorsen P. Autism prevalence trends over time in Denmark: changes in prevalence and age at diagnosis. Arch Pediatr Adolesc Med 2008; 162:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/36\">",
"      Hertz-Picciotto I, Delwiche L. The rise in autism and the role of age at diagnosis. Epidemiology 2009; 20:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/37\">",
"      Fombonne E, Zakarian R, Bennett A, et al. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006; 118:e139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/38\">",
"      Muhle R, Trentacoste SV, Rapin I. The genetics of autism. Pediatrics 2004; 113:e472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/39\">",
"      Bolton P, Macdonald H, Pickles A, et al. A case-control family history study of autism. J Child Psychol Psychiatry 1994; 35:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/40\">",
"      Jorde LB, Hasstedt SJ, Ritvo ER, et al. Complex segregation analysis of autism. Am J Hum Genet 1991; 49:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/41\">",
"      Piven J, Gayle J, Chase GA, et al. A family history study of neuropsychiatric disorders in the adult siblings of autistic individuals. J Am Acad Child Adolesc Psychiatry 1990; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/42\">",
"      Risch N, Spiker D, Lotspeich L, et al. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet 1999; 65:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/43\">",
"      Asherson PJ, Curran S. Approaches to gene mapping in complex disorders and their application in child psychiatry and psychology. Br J Psychiatry 2001; 179:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/44\">",
"      Ozonoff S, Young GS, Carter A, et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 2011; 128:e488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/45\">",
"      Rapin I. Autism. N Engl J Med 1997; 337:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/46\">",
"      Filipek PA, Accardo PJ, Ashwal S, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000; 55:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/47\">",
"      Tuchman RF, Rapin I, Shinnar S. Autistic and dysphasic children. II: Epilepsy. Pediatrics 1991; 88:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/48\">",
"      Ballaban-Gil K, Tuchman R. Epilepsy and epileptiform EEG: association with autism and language disorders. Ment Retard Dev Disabil Res Rev 2000; 6:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/49\">",
"      Parmeggiani A, Posar A, Antolini C, et al. Epilepsy in patients with pervasive developmental disorder not otherwise specified. J Child Neurol 2007; 22:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/50\">",
"      Mouridsen SE, Rich B, Isager T. A longitudinal study of epilepsy and other central nervous system diseases in individuals with and without a history of infantile autism. Brain Dev 2011; 33:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/51\">",
"      Woolfenden S, Sarkozy V, Ridley G, et al. A systematic review of two outcomes in autism spectrum disorder - epilepsy and mortality. Dev Med Child Neurol 2012; 54:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/52\">",
"      Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005; 162:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/53\">",
"      Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. Dev Med Child Neurol 1996; 38:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/54\">",
"      Battaglia A, Carey JC. Etiologic yield of autistic spectrum disorders: a prospective study. Am J Med Genet C Semin Med Genet 2006; 142C:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/55\">",
"      Rutter M, Bailey A, Bolton P, Le Couteur A. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994; 35:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/56\">",
"      Cohen D, Pichard N, Tordjman S, et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord 2005; 35:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/57\">",
"      Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord 1998; 28:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/58\">",
"      Wong V. Study of the relationship between tuberous sclerosis complex and autistic disorder. J Child Neurol 2006; 21:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/59\">",
"      Numis AL, Major P, Montenegro MA, et al. Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex. Neurology 2011; 76:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/60\">",
"      Gillberg IC, Gillberg C, Ahls&eacute;n G. Autistic behaviour and attention deficits in tuberous sclerosis: a population-based study. Dev Med Child Neurol 1994; 36:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/61\">",
"      Curatolo P, Cusmai R, Cortesi F, et al. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci 1991; 615:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/62\">",
"      Demark JL, Feldman MA, Holden JJ. Behavioral relationship between autism and fragile x syndrome. Am J Ment Retard 2003; 108:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/63\">",
"      Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 2001; 22:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/64\">",
"      Hashimoto O, Shimizu Y, Kawasaki Y. Brief report: low frequency of the fragile X syndrome among Japanese autistic subjects. J Autism Dev Disord 1993; 23:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/65\">",
"      Klauck SM, M&uuml;nstermann E, Bieber-Martig B, et al. Molecular genetic analysis of the FMR-1 gene in a large collection of autistic patients. Hum Genet 1997; 100:224.",
"     </a>",
"    </li>",
"    <li>",
"     Online Mendelian Inheritance in Man. Autism (%209850) file://omim.org/entry/209850 (Accessed on August 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/67\">",
"      Veltman MW, Craig EE, Bolton PF. Autism spectrum disorders in Prader-Willi and Angelman syndromes: a systematic review. Psychiatr Genet 2005; 15:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/68\">",
"      Sikora DM, Pettit-Kekel K, Penfield J, et al. The near universal presence of autism spectrum disorders in children with Smith-Lemli-Opitz syndrome. Am J Med Genet A 2006; 140:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/69\">",
"      Bukelis I, Porter FD, Zimmerman AW, Tierney E. Smith-Lemli-Opitz syndrome and autism spectrum disorder. Am J Psychiatry 2007; 164:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/70\">",
"      Baron-Cohen S. Two new theories of autism: hyper-systemising and assortative mating. Arch Dis Child 2006; 91:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/71\">",
"      Samaco RC, Nagarajan RP, Braunschweig D, LaSalle JM. Multiple pathways regulate MeCP2 expression in normal brain development and exhibit defects in autism-spectrum disorders. Hum Mol Genet 2004; 13:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/72\">",
"      Lopez-Rangel E, Lewis ME. Loud and clear evidence for gene silencing by epigenetic mechanisms in autism spectrum and related neurodevelopmental disorders. Clin Genet 2006; 69:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/73\">",
"      Bailey A, Le Couteur A, Gottesman I, et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 1995; 25:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/74\">",
"      Folstein S, Rutter M. Infantile autism: a genetic study of 21 twin pairs. J Child Psychol Psychiatry 1977; 18:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/75\">",
"      Ritvo ER, Spence MA, Freeman BJ, et al. Evidence for autosomal recessive inheritance in 46 families with multiple incidences of autism. Am J Psychiatry 1985; 142:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/76\">",
"      Rosenberg RE, Law JK, Yenokyan G, et al. Characteristics and concordance of autism spectrum disorders among 277 twin pairs. Arch Pediatr Adolesc Med 2009; 163:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/77\">",
"      Lichtenstein P, Carlstr&ouml;m E, R&aring;stam M, et al. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010; 167:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/78\">",
"      Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/79\">",
"      Bacchelli E, Maestrini E. Autism spectrum disorders: molecular genetic advances. Am J Med Genet C Semin Med Genet 2006; 142C:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/80\">",
"      Eichler EE, Zimmerman AW. A hot spot of genetic instability in autism. N Engl J Med 2008; 358:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/81\">",
"      Sebat J, Lakshmi B, Malhotra D, et al. Strong association of de novo copy number mutations with autism. Science 2007; 316:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/82\">",
"      Pinto D, Pagnamenta AT, Klei L, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010; 466:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/83\">",
"      Salyakina D, Cukier HN, Lee JM, et al. Copy number variants in extended autism spectrum disorder families reveal candidates potentially involved in autism risk. PLoS One 2011; 6:e26049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/84\">",
"      Shen Y, Dies KA, Holm IA, et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010; 125:e727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/85\">",
"      Cook EH Jr, Lindgren V, Leventhal BL, et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 1997; 60:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/86\">",
"      Wolpert CM, Menold MM, Bass MP, et al. Three probands with autistic disorder and isodicentric chromosome 15. Am J Med Genet 2000; 96:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/87\">",
"      Weiss LA, Shen Y, Korn JM, et al. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med 2008; 358:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/88\">",
"      Baker P, Piven J, Schwartz S, Patil S. Brief report: duplication of chromosome 15q11-13 in two individuals with autistic disorder. J Autism Dev Disord 1994; 24:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/89\">",
"      Cheng Y, Qin G, Dai X, Zhao Y. NPY1, a BTB-NPH3-like protein, plays a critical role in auxin-regulated organogenesis in Arabidopsis. Proc Natl Acad Sci U S A 2007; 104:18825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/90\">",
"      Volkmar FR, Pauls D. Autism. Lancet 2003; 362:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/91\">",
"      Shao Y, Wolpert CM, Raiford KL, et al. Genomic screen and follow-up analysis for autistic disorder. Am J Med Genet 2002; 114:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/92\">",
"      Liu J, Nyholt DR, Magnussen P, et al. A genomewide screen for autism susceptibility loci. Am J Hum Genet 2001; 69:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/93\">",
"      Durand CM, Betancur C, Boeckers TM, et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007; 39:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/94\">",
"      Autism Genome Project Consortium, Szatmari P, Paterson AD, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/95\">",
"      Alarc&oacute;n M, Abrahams BS, Stone JL, et al. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 2008; 82:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/96\">",
"      Arking DE, Cutler DJ, Brune CW, et al. A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 2008; 82:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/97\">",
"      Bakkaloglu B, O'Roak BJ, Louvi A, et al. Molecular cytogenetic analysis and resequencing of contactin associated protein-like 2 in autism spectrum disorders. Am J Hum Genet 2008; 82:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/98\">",
"      Wang K, Zhang H, Ma D, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature 2009; 459:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/99\">",
"      Nurmi EL, Dowd M, Tadevosyan-Leyfer O, et al. Exploratory subsetting of autism families based on savant skills improves evidence of genetic linkage to 15q11-q13. J Am Acad Child Adolesc Psychiatry 2003; 42:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/100\">",
"      Bolton PF, Dennis NR, Browne CE, et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. Am J Med Genet 2001; 105:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/101\">",
"      International Molecular Genetic Study of Autism Consortium (IMGSAC). A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am J Hum Genet 2001; 69:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/102\">",
"      Boddaert N, Zilbovicius M, Philipe A, et al. MRI findings in 77 children with non-syndromic autistic disorder. PLoS One 2009; 4:e4415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/103\">",
"      Baron-Cohen S, Ring HA, Wheelwright S, et al. Social intelligence in the normal and autistic brain: an fMRI study. Eur J Neurosci 1999; 11:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/104\">",
"      Happ&eacute; F, Ehlers S, Fletcher P, et al. 'Theory of mind' in the brain. Evidence from a PET scan study of Asperger syndrome. Neuroreport 1996; 8:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/105\">",
"      Lainhart JE. Advances in autism neuroimaging research for the clinician and geneticist. Am J Med Genet C Semin Med Genet 2006; 142C:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/106\">",
"      Courchesne E, Karns CM, Davis HR, et al. Unusual brain growth patterns in early life in patients with autistic disorder: an MRI study. Neurology 2001; 57:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/107\">",
"      Pelphrey K, Adolphs R, Morris JP. Neuroanatomical substrates of social cognition dysfunction in autism. Ment Retard Dev Disabil Res Rev 2004; 10:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/108\">",
"      Bonilha L, Cendes F, Rorden C, et al. Gray and white matter imbalance--typical structural abnormality underlying classic autism? Brain Dev 2008; 30:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/109\">",
"      Chen R, Jiao Y, Herskovits EH. Structural MRI in autism spectrum disorder. Pediatr Res 2011; 69:63R.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/110\">",
"      Piven J, Arndt S, Bailey J, et al. An MRI study of brain size in autism. Am J Psychiatry 1995; 152:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/111\">",
"      Piven J, Arndt S, Bailey J, Andreasen N. Regional brain enlargement in autism: a magnetic resonance imaging study. J Am Acad Child Adolesc Psychiatry 1996; 35:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/112\">",
"      Courchesne E, Mouton PR, Calhoun ME, et al. Neuron number and size in prefrontal cortex of children with autism. JAMA 2011; 306:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/113\">",
"      Castelli F, Frith C, Happ&eacute; F, Frith U. Autism, Asperger syndrome and brain mechanisms for the attribution of mental states to animated shapes. Brain 2002; 125:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/114\">",
"      M&uuml;ller RA, Kleinhans N, Kemmotsu N, et al. Abnormal variability and distribution of functional maps in autism: an FMRI study of visuomotor learning. Am J Psychiatry 2003; 160:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/115\">",
"      Gervais H, Belin P, Boddaert N, et al. Abnormal cortical voice processing in autism. Nat Neurosci 2004; 7:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/116\">",
"      Hadjikhani N, Joseph RM, Snyder J, et al. Activation of the fusiform gyrus when individuals with autism spectrum disorder view faces. Neuroimage 2004; 22:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/117\">",
"      Pierce K, Haist F, Sedaghat F, Courchesne E. The brain response to personally familiar faces in autism: findings of fusiform activity and beyond. Brain 2004; 127:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/118\">",
"      Piggot J, Kwon H, Mobbs D, et al. Emotional attribution in high-functioning individuals with autistic spectrum disorder: a functional imaging study. J Am Acad Child Adolesc Psychiatry 2004; 43:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/119\">",
"      Wang AT, Dapretto M, Hariri AR, et al. Neural correlates of facial affect processing in children and adolescents with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 2004; 43:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/120\">",
"      Grelotti DJ, Klin AJ, Gauthier I, et al. fMRI activation of the fusiform gyrus and amygdala to cartoon characters but not to faces in a boy with autism. Neuropsychologia 2005; 43:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/121\">",
"      Williams JH, Waiter GD, Gilchrist A, et al. Neural mechanisms of imitation and 'mirror neuron' functioning in autistic spectrum disorder. Neuropsychologia 2006; 44:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/122\">",
"      Dalton KM, Nacewicz BM, Johnstone T, et al. Gaze fixation and the neural circuitry of face processing in autism. Nat Neurosci 2005; 8:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/123\">",
"      Chandana SR, Behen ME, Juh&aacute;sz C, et al. Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int J Dev Neurosci 2005; 23:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/124\">",
"      McPartland J, Dawson G, Webb SJ, et al. Event-related brain potentials reveal anomalies in temporal processing of faces in autism spectrum disorder. J Child Psychol Psychiatry 2004; 45:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/125\">",
"      Bailey AJ, Braeutigam S, Jousm&auml;ki V, Swithenby SJ. Abnormal activation of face processing systems at early and intermediate latency in individuals with autism spectrum disorder: a magnetoencephalographic study. Eur J Neurosci 2005; 21:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/126\">",
"      Grice SJ, Halit H, Farroni T, et al. Neural correlates of eye-gaze detection in young children with autism. Cortex 2005; 41:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/127\">",
"      Ceponiene R, Lepist&ouml; T, Shestakova A, et al. Speech-sound-selective auditory impairment in children with autism: they can perceive but do not attend. Proc Natl Acad Sci U S A 2003; 100:5567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/128\">",
"      Kasai K, Hashimoto O, Kawakubo Y, et al. Delayed automatic detection of change in speech sounds in adults with autism: a magnetoencephalographic study. Clin Neurophysiol 2005; 116:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/129\">",
"      Alc&aacute;ntara JI, Weisblatt EJ, Moore BC, Bolton PF. Speech-in-noise perception in high-functioning individuals with autism or Asperger's syndrome. J Child Psychol Psychiatry 2004; 45:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/130\">",
"      Teder-S&auml;lej&auml;rvi WA, Pierce KL, Courchesne E, Hillyard SA. Auditory spatial localization and attention deficits in autistic adults. Brain Res Cogn Brain Res 2005; 23:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/131\">",
"      Bauman ML, Kemper TL. The neuropathology of the autism spectrum disorders: what have we learned? Novartis Found Symp 2003; 251:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/132\">",
"      Gardener H, Spiegelman D, Buka SL. Perinatal and neonatal risk factors for autism: a comprehensive meta-analysis. Pediatrics 2011; 128:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/133\">",
"      Pinto-Martin JA, Levy SE, Feldman JF, et al. Prevalence of autism spectrum disorder in adolescents born weighing &lt;2000 grams. Pediatrics 2011; 128:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/134\">",
"      Krakowiak P, Walker CK, Bremer AA, et al. Maternal metabolic conditions and risk for autism and other neurodevelopmental disorders. Pediatrics 2012; 129:e1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/135\">",
"      Reichenberg A, Gross R, Weiser M, et al. Advancing paternal age and autism. Arch Gen Psychiatry 2006; 63:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/136\">",
"      Croen LA, Najjar DV, Fireman B, Grether JK. Maternal and paternal age and risk of autism spectrum disorders. Arch Pediatr Adolesc Med 2007; 161:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/137\">",
"      Gardener H, Spiegelman D, Buka SL. Prenatal risk factors for autism: comprehensive meta-analysis. Br J Psychiatry 2009; 195:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/138\">",
"      Grether JK, Anderson MC, Croen LA, et al. Risk of autism and increasing maternal and paternal age in a large north American population. Am J Epidemiol 2009; 170:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/139\">",
"      Durkin MS, Maenner MJ, Newschaffer CJ, et al. Advanced parental age and the risk of autism spectrum disorder. Am J Epidemiol 2008; 168:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/140\">",
"      Gabis L, Raz R, Kesner-Baruch Y. Paternal age in autism spectrum disorders and ADHD. Pediatr Neurol 2010; 43:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/141\">",
"      Sandin S, Hultman CM, Kolevzon A, et al. Advancing maternal age is associated with increasing risk for autism: a review and meta-analysis. J Am Acad Child Adolesc Psychiatry 2012; 51:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/37/4698/abstract/142\">",
"      Kong A, Frigge ML, Masson G, et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 2012; 488:471.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 595 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-219.243.220.100-9E6818F356-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4698=[""].join("\n");
var outline_f4_37_4698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Autistic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rett disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Childhood disintegrative disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Asperger disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PDD-not otherwise specified",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Rate in siblings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Associated conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2160246736\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neurobiologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2160246807\">",
"      Environmental and perinatal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Parental age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Lack of association with immunizations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/6/29804\" title=\"table 1\">",
"      DSM IV criteria autism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/57/13212\" title=\"table 2\">",
"      DSM IV criteria Asperger disorder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/20/15689?source=related_link\">",
"      Asperger disorder: Clinical features and diagnosis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/54/872?source=related_link\">",
"      Autism spectrum disorders in children and adolescents: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/38/21097?source=related_link\">",
"      Basic principles of genetic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38969?source=related_link\">",
"      Diagnosis of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/8/16516?source=related_link\">",
"      Epidemiology and genetics of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/46/41699?source=related_link\">",
"      Patient information: Autism spectrum disorders (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/29/32218?source=related_link\">",
"      Rett syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=related_link\">",
"      Surveillance and screening for autism spectrum disorders in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/38/34410?source=related_link\">",
"      Tuberous sclerosis complex: Genetics, clinical features, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_37_4699="Late cardiovasc death preeclamp";
var content_f4_37_4699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Deaths from cardiovascular causes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relative hazard rate (95 percent confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonpreeclamptic, term delivery",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonpreeclamptic, preterm delivery",
"       </td>",
"       <td>",
"        2.95 (2.12 to 4.11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclamptic, term delivery",
"       </td>",
"       <td>",
"        1.65 (1.01 to 2.70)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Preeclamptic, preterm delivery",
"       </td>",
"       <td>",
"        8.12 (4.31 to 15.33)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Irgens, HU, Reisaeter, L, Irgens, LM, Lie, RT. BMJ 2001; 323:1213.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4699=[""].join("\n");
var outline_f4_37_4699=null;
var title_f4_37_4700="Agents for which activated charcoal is not recommended";
var content_f4_37_4700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents for which activated charcoal is not recommended",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Heavy metals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arsenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mercury",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zinc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cadmium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inorganic ions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lithium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Potassium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iodide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Boric acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Corrosives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkali",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkanes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkenes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alkyl halides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aromatic hydrocarbons",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alcohols",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acetone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isopropanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methanol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Essential oils",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4700=[""].join("\n");
var outline_f4_37_4700=null;
var title_f4_37_4701="US scheds controlled drugs";
var content_f4_37_4701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F66064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F66064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Schedules of controlled substances in the United States*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Schedule",
"      </td>",
"      <td class=\"subtitle1\">",
"       Examples",
"      </td>",
"      <td class=\"subtitle1\">",
"       Medical use?",
"      </td>",
"      <td class=\"subtitle1\">",
"       Potential for abuse/dependence",
"      </td>",
"      <td class=\"subtitle1\">",
"       Prescription",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I",
"      </td>",
"      <td>",
"       Heroin, marijuana, LSD&bull;",
"      </td>",
"      <td>",
"       No",
"      </td>",
"      <td>",
"       High",
"      </td>",
"      <td>",
"       N/A",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       II",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Narcotics:",
"      </td>",
"      <td rowspan=\"6\">",
"       Yes",
"      </td>",
"      <td rowspan=\"6\">",
"       High",
"      </td>",
"      <td rowspan=\"6\">",
"       Require a written prescription by a licensed practitioner. Refilling of individual prescriptions is prohibited.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Codeine",
"       </p>",
"       <p>",
"        - Fentanyl",
"       </p>",
"       <p>",
"        - Hydromorphone",
"       </p>",
"       <p>",
"        - Morphine",
"       </p>",
"       <p>",
"        - Methadone",
"       </p>",
"       <p>",
"        - Oxycodone",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Stimulants:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Amphetamine",
"       </p>",
"       <p>",
"        - Methamphetamine",
"       </p>",
"       <p>",
"        - Methylphenidate",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Other:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Cocaine",
"       </p>",
"       <p>",
"        - Pentobarbital, secobarbital",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       III",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Narcotics:",
"      </td>",
"      <td rowspan=\"4\">",
"       Yes",
"      </td>",
"      <td rowspan=\"4\">",
"       Less than with Schedule I and II drugs",
"      </td>",
"      <td rowspan=\"9\">",
"       A prescription for a drug in Schedules III through V must be issued by a practitioner and may be communicated orally, in writing, or by facsimile to the pharmacist; may be refilled up to five times",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Buprenorphine",
"       </p>",
"       <p>",
"        - Combination products with &lt;15 mg hydrocodone/unit (eg, Vicodin) or &lt;90 mg codeine/unit (eg, Tylenol with codeine)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Non-narcotics:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Dronabinol",
"       </p>",
"       <p>",
"        - Ketamine",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       IV",
"      </td>",
"      <td class=\"sublist1_start\">",
"       Narcotics:",
"      </td>",
"      <td rowspan=\"4\">",
"       Yes",
"      </td>",
"      <td rowspan=\"4\">",
"       Less than with Schedule III drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       - Propoxyphene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Others:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       <p>",
"        - Alprazolam",
"       </p>",
"       <p>",
"        - Diazepam",
"       </p>",
"       <p>",
"        - Clonazepam",
"       </p>",
"       <p>",
"        - Lorazepam",
"       </p>",
"       <p>",
"        - Midazolam",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       V",
"      </td>",
"      <td>",
"       Preparations containing limited quantities of certain narcotic and stimulant drugs used for antitussive, antidiarrheal and analgesic purposes (eg, cough preparation with &lt;200 mg codeine/100 mL (eg, Robitussin AC)",
"      </td>",
"      <td>",
"       Yes",
"      </td>",
"      <td>",
"       Lower than with Schedule IV drugs",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Drugs and other substances that are considered controlled substances under the Controlled Substances Act are divided into five schedules based upon whether they have a currently accepted medical use in the United States and their relative abuse potential and likelihood of causing dependence when abused.",
"     <br>",
"      &bull; Lysergic acid diethylamide",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4701=[""].join("\n");
var outline_f4_37_4701=null;
var title_f4_37_4702="Cardiac output during labor";
var content_f4_37_4702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cardiac output during normal labor, delivery, and postpartum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 286px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonica, JJ, McDonald, JS. Principles and Practice of Obstetric Analgesia and Anesthesia, 2nd ed, Williams &amp;Wilkins, Baltimore, 1994. p. 62.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4702=[""].join("\n");
var outline_f4_37_4702=null;
var title_f4_37_4703="Postop nomogram sarcoma";
var content_f4_37_4703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Postoperative nomogram for 12-year sarcoma-specific death based upon data from 2,163 patients treated at memorial Sloan-Kettering cancer center",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 412px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Instructions for physician:",
"    </strong>",
"    Locate the patient's tumor size on the Size axis. Draw a line straight upwards to the Points axis to determine how many points towards sarcoma-specific death the patient receives for tumor size. Repeat this process for the other axes, each time drawing straight upward to the Points axis. Sum the points achieved for each predictor, and locate this sum on the Total Points axis. Draw a line straight down to either the Low Grade or High Grade axis to find the patient's probability of dying from sarcoma within 12 years assuming he or she does not die of another cause first.",
"    <strong>",
"     Instructions to patient:",
"    </strong>",
"    \"If we had 100 patients exactly like you, we would expect between (predicted percentage from nomogram - 8 percent) and (predicted percentage + 8 percentage) to die of sarcoma within 12 years if they did not die of another cause first. Death from sarcoma after 12 years is still possible.\"",
"    <div class=\"footnotes\">",
"     Fibro: fibrosarcoma; Lipo: liposarcoma; Leiomyo: leiomyosarcoma; MFH: malignant fibrous histiocytoma; MPNT: malignant peripheral-nerve tumor; SSD: sarcoma-specific death.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kattan MW, Leung DHY, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Onc 2002; 20:791. Copyright &copy; 2002 American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_37_4703=[""].join("\n");
var outline_f4_37_4703=null;
       